Immune targets in the tumor microenvironment treated by radiotherapy. by Ozpiskin, Omer M et al.
UC Davis
UC Davis Previously Published Works
Title
Immune targets in the tumor microenvironment treated by radiotherapy.
Permalink
https://escholarship.org/uc/item/6j3454kh
Journal
Theranostics, 9(5)
ISSN
1838-7640
Authors
Ozpiskin, Omer M
Zhang, Lu
Li, Jian Jian
Publication Date
2019-01-30
DOI
10.7150/thno.32648
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Theranostics 2019, Vol. 9, Issue 5 
 
 
http://www.thno.org 
1215 
Theranostics 
2019; 9(5): 1215-1231. doi: 10.7150/thno.32648 
Review 
Immune targets in the tumor microenvironment treated 
by radiotherapy 
Omer M. Ozpiskin1#, Lu Zhang1#, and Jian Jian Li1,2 
1. Department of Radiation Oncology, University of California at Davis, Sacramento, California USA 
2. NCI-designated Comprehensive Cancer Center, University of California at Davis, Sacramento, California USA 
#Equally contributed to this work.  
 Corresponding author: : Jian Jian Li, MD, PhD. Department of Department of Radiation Oncology, University of California at Davis, School of Medicine, 
University of California Davis; Room 2005, Research Building II, 4625 2nd Ave, Sacramento, CA 95817, USA. Tel: (001)-916-7035174; Email: jijli@ucdavis.edu 
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license 
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. 
Received: 2018.12.28; Accepted: 2019.01.11; Published: 2019.01.30 
Abstract 
Radiotherapy (RT), the major anti-cancer modality for more than half of cancer patients after 
diagnosis, has the advantage of local tumor control with relatively less systematic side effects 
comparing to chemotherapy. However, the efficacy of RT is limited by acquired tumor resistance 
leading to the risks of relapse and metastasis. To further enhance the efficacy of RT, with the 
renaissances of targeted immunotherapy (TIT), increasing interests are raised on RT combined with 
TIT including cancer vaccines, T-cell therapy, and antibody-based immune checkpoint blockers 
(ICB) such as anti-CTLA-4 and anti-PD1/PD-L1. In achieving a significant synergy between RT and 
TIT, the dynamics of radiation-induced response in tumor cells and stromal cells, especially the 
cross-talk between tumor cells and immune cells in the irradiated tumor microenvironment (ITME) 
as highlighted in recent literature are to be elucidated. The abscopal effect refereeing the 
RT-induced priming function outside of ITME could be compromised by the immune-suppressive 
factors such as CD47 and PD-L1 on tumor cells and Treg induced or enhanced in the ITME. Cell 
surface receptors temporally or permanently induced and bioactive elements released from dead 
cells could serve antigenic source (radiation-associated antigenic proteins, RAAPs) to the host and 
have functions in immune regulation on the tumor. This review is attempted to summarize a cluster 
of factors that are inducible by radiation and targetable by antibodies, or have potential to be 
immune regulators to synergize tumor control with RT. Further characterization of immune 
regulators in ITME will deepen our understanding of the interplay among immune regulators in ITME 
and discover new effective targets for the combined modality with RT and TIT. 
Key words: radiation therapy; irradiated tumor microenvironment, immune regulation, radiation-associated 
antigenic proteins, CD47, PD-1, PD-L1, HER2, tumor associated macrophage 
Introduction 
Both pro- and anti-tumor immune responses 
could be induced in tumor microenvironment under 
therapeutic radiation. The anti-tumor response (the 
abscopal effect) is observed in several human cancers 
treated with RT and the potential synergy for 
enhancing the cancer control is indicated in the 
combined therapy with RT and TIT [1-3]. In addition 
to the well-defined checkpoint inhibitors PD-1 and 
PD-L1, exploration of other potential immune targets 
that are responsive to radiation in ITME will provide 
critical information in inventing more effective 
therapeutic modalities. Among the numerous 
IR-induced proteins, only a few of them are enhanced 
or induced temporally or permanently on the surface 
of tumor cells and could be targetable by immune 
approaches. Except the well-studied ‘direct targets’ of 
radiation such as DNA molecule in the nucleus, 
accumulating reports revealed ‘indirect targets’ on 
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stromal cells in the irradiated local microenvironment 
as well as the cells distant to the tumor [4, 5]. One of 
the observed indirect effects is the radiation-induced 
reconstruction of tumor microenvironment including 
release of cytokines from the irradiated cells, 
recruitment of antigen presenting cells, and 
expressions of new molecules or enhancement of 
original receptors at the cell membrane of tumor cells 
or immune cells [2, 6-9]. Radiation is shown to 
increase the diversity of the T-cell receptor (TCR) 
repertoire of intratumoral T cells [10]. Recent data 
generated by RT combined with TIT to treat 
metastatic cancer support the concept that the indirect 
effects of ionizing radiation (IR) are at least in part due 
to systemic antitumor immunity [11]. In addition, RT 
with TIT shows a synergic potentiation in improving 
immune repertoire [12, 13] and enhances cell surface 
epitopes processed and presented in RT treated 
tumors [5]. These results resuscitate the long-time 
holding abscopal effect which is in favor of a 
pro-immune and anti-cancer direction [14-16]. Thus, 
the challenge could be further characterization and 
identification of such pro-immune elements in the 
ITME.  
In the ITME, RT-associated pro-immune factors 
could be mixed with the radiation-mediated immune 
suppressors such as inhibition on M2 macrophage 
transformation and recruitment of immune 
modulator cells [17-19]. It is thus suggested that the 
strategy of RT/TIT will meet several challenges 
including the absence or downregulation of major 
histocompatibility antigens (MHC), weak expression 
or presentation of antigenic proteins, and 
anti-inflammatory environment in irradiated tumor 
microenvironment [20]. Such IR-associated pro-tumor 
immune response [21] could severely compromise the 
RT-induced priming immune response (abscopal 
effect, in the following section). Thus to enhance the 
tumor response to RT-TIT, the balance of 
anti-/pro-cancer immune regulation [2] needs to be 
further investigated. With the increasing interests and 
potential clinical benefits of RT combined with TIT, 
multiple level regulations observed in irradiated 
tumor microenvironment including tumor 
vasculature, immune elements, antigen visibility, 
stromal and immunological alternations are well 
discussed in a series of seminal reviews [4, 22, 23]. The 
timing and dynamics of specific immune elements 
induced or enhanced in a given ITME is to be 
investigated. Thus, current under-focused 
developments are the RT-induced cell surface 
molecules on tumor cells that can be RT-inducible and 
immune-targetable as well.  
Abscopal effect 
Radiation-associated potential priming function 
in immune regulation is a long recognized 
phenomenon [24-26]. The term abscopal effect created 
by RH Mole describes a relatively rare situation that 
“an action at a distance from the irradiated volume 
but within the same organism” [27]. It has been 
observed that systemic immune modulatory factors 
induced by radiation have distinct immune effects on 
cancer cells [28]. Although the exact mechanism 
remains to be elucidated, the abscopal effect is linked 
with the response of untreated lesions via a process 
termed “immunogenic cell death” (ICD) that helps the 
release of endogenous damage associated molecular 
patterns (DAMPs). Some of the DAMPs including 
calreticulin (eat me signaling), high-mobility group 
box 1 protein (HMGB1), and adenosine triphosphate 
(ATP) have been identified to play a role in activating 
the immune system and causing antigen presentation 
to T cells [4, 29, 30] (Fig. 1). For instance, the HMGB1 
acts as a pro-inflammatory mediator to enhance the 
generation of cytokines such as TNFα, IL-1, IL-6, and 
IL-8 [31] and tumor antigen presentation by binding 
to the toll-like receptor 4 (TLR4) on dendritic cells 
(DCs). In addition, the released DNA fragments from 
radiation-induced cell death are also able to stimulate 
the expression of interferon gene (STING) in DCs and 
thus to enhance DCs cross-priming [32]. As low as a 
single dose of 0.5 Gy ionizing irradiation is shown to 
recruit NOS2-expressing macrophages to the tumors 
and increase T cell infiltration in the irradiated tumors 
[33], indicating a potential synergy on tumor control 
by RT combined with targeted immunotherapy.  
Accumulating reports indicate that irradiated 
tumor cells can release an array of chemokines 
including CXCL16 and CXCL10 to enhance the 
expression of adhesion molecules E-selectin and 
ICAM-1 in endothelial cells and MHC, Fas, ICAM-1, 
and NKG2D ligands [35-41]. The potential abscopal 
function is recently well-summarized with RT-treated 
23 clinical cases in an array of human cancers [42]. 
Another decent review has further demonstrated the 
abscopal effect in clinical RT treatments due to 
immunogenic cell death via releasing HMGB1 [30] as 
well as tumor neoantigens (a term used to describe a 
patient-specific tumor antigen resulted from 
mutations during oncogenesis or by RT) [43, 44]. 
During this process, radiation derived DAMPs is 
required for APCs (antigen-presenting cells) 
activation and phagocytosis [30]. Additionally, IR 
induces NK2GD on cancer cells resulting in the 
promotion of natural killer cells’ cytotoxic response 
[45]. All of these actions are able to lead the 
visualization of tumor cells by immune system with 
systemic immune stimulations, which not only 
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attracts primary tumors but is also believed to have an 
inhibitory function on metastatic lesions.  
According to the meta-analysis by Marconi et al, 
the abscopal effect shows a dose-dependent pattern in 
response to IR [46]. Although the optimum dose 
required for maximizing abscopal effect remains 
controversial [30, 47], identification of ideal RT 
scheme such as low or high fractionated doses may 
generate groundbreaking advantage in clinical 
practice. On the other hand, the molecular mechanism 
underlying abscopal effect is to be elucidated. Among 
the signaling pathways responsible for genotoxic 
stresses, the transcription factor NF-κB, a master 
regulator in inflammation and acute innate immune 
response, is well-defined to be sensitive to radiation 
stress and immune regulation [48, 49] and has been 
linked with abscopal effect [50, 51]. Since the target 
genes of NF-κB can be induced in both tumor cells 
and immune cells in ITME, in the following section, 
NF-κB-mediated gene regulation in radiation- 
associated immune response is discussed. 
NF-κB effector genes in 
radiation-associated immune response  
NF-κB is a crucial transcription factor that 
regulates a wide scale of genes involved in both cell 
stress and immunity responses [8, 49, 52]. NF-κB 
modulates effector genes involved in cellular stress 
responses, cytokines production, cell survival and 
metastasis via different homo- or hetero-dimerization 
of subunits RelA/p65, c-Rel, RelB, p50, and p52 [53, 
54]. Generally, the activation of NF-κB functions in 
two major mechanisms, i.e., canonical and 
non-canonical pathways (Fig. 2). Radiation-induced 
NF-κB is mostly mediated via IKK-dependent 
canonical pathway. In addition to ROS-mediated 
activation of protein kinase in cell membrane 
receptors such as TNF-α [55, 56] and HER2 [57, 58], 
the signals of IR-induced DNA damages in the 
nucleus can activate ATM/SUMO/NEMO pathway 
to enhance NF-κB nuclear translocation and gene 
transcription [59]. This response is generally viewed 
as NF-κB-mediated DNA repair mechanism which 
influences the intrinsic radiation sensitivity and 
adaptive capacity of tumor cells in ITME such as the 
activation of IKKα/IKKβ/NEMO-dependent or 
-independent signaling pathways under the stress of 
genotoxicity [60]. In the non-canonical pathway, 
RelB/p52 is activated depending upon the inducible 
p100 involved in lymphoid organogenesis, B-cell 
survival and maturation, DCs activation and bone 
metabolism [61].  
 
Figure 1. Abscopal effect and RAAPs in irradiated tumor microenvironment (ITME). RT shrinks the local tumor but may also affect the distant lesions due to 
immunoregulation initiated by local tumor microenvironment (abscopal effect). RT can induce cell death, RAAPs (radiation-associated antigenic proteins), and immunogenic 
factors or cytokines, which can individually or synergistically to priming immune system via triggering the release of so called endogenous danger signals as damage-associated 
molecular patterns (DAMPs) and the activation of immune cells. The RAAPs and DAMPs contribute to priming of the immune system and activating immune mechanisms in a 
heterogenic tumor microenvironment (more information can be referred in [34]). 
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Figure 2. Activation of NF-κB in ITME. Radiation can induce NF-κB activation in both tumor and stromal cells including immune cells in ITME. The subunits RelA (p65), 
c-Rel, RelB, p105/p50, and p100/p52 can form active homo- or hetero- dimeric complex and activated by the canonical and non-canonical pathway [62, 63]. Radiation-induced 
NF-κB is mainly via canonical pathway that is divided into two categories: IKK-dependent or IKK-independent. The IκB is degraded upon phosphorylation by IKK which relocates 
NF-κB dimer (p50/p65) to nucleus for transcription of radiation-target genes including RAAPs such as CD47, HER2, and PD-1/PD-L1. UV or hypoxia activates NF-κB via 
IKK-independent phosphorylation of IκB in which RelB/p52 is activated via metabolism of p100. On the other hand, radiation-induced DNA damage activates nuclear ATM that 
also enhances NF-κB via regulation of IKK activity [8, 9, 64]. The reactive oxygen species (ROS) produced by radiation triggers the NF-κB signaling in cytoplasm by IKK complex 
phosphorylation [65], while inhibits NF-κB signaling via oxidation of IKKɣ in cytoplasm or oxidation of p50 in nucleus. The canonical pathway impacts various biological processes, 
including immune response, inflammation, and cell growth and survival. The non-canonical pathway regulates important biological functions, including lymphoid organogenesis, 
B-cell maturation and DC activation. 
 
A unique role of NF-κB in the ITME is indicated 
by its gene regulating functions in both tumor cells 
and immune cells [66]. NF-κB is activated not only by 
IR-induced nuclear DNA damage via ATM in the 
stressed tumor cells, but also by IR-induced cytokines 
[8, 67]. Radiation increased inflammation in tumor by 
activating the NF-κB pathway induces expressions of 
pro-inflammatory cytokines. The translocation of 
NF-κB complex to the nucleus through both canonical 
and non-canonical pathways induces various 
pro-inflammatory gene expression including TNFα, 
IL-6, IL-1α and IL-1β. Such inflammatory response 
coupled with potential release of RAAPs may enhance 
DCs maturation and prime tumor specific T cells [68]. 
In doubly deficient p50/RelA or p50/c-Rel mice, the 
development and function of DCs were significantly 
impaired and IL-12 expression was abolished, 
suggesting that DC development is linked with the 
canonical NF-κB pathway [69]. Sauter et al 
demonstrated that necrotic tumor cells were 
necessary to mature DCs that then primed CD8+ T 
cells [70]. Hou et al demonstrated that impaired 
canonical NF-κB pathway could also reduce RT 
efficacy, indicating the canonical NF-κB-induced 
immune response in ITME. The same report also 
suggested that the non-canonical pathway in DC cells 
activated by STING pathway inhibited the release of 
IFN and blockage of p52-RelB nuclear translocation 
contributed to radiotherapy enhancement [71]. 
HMGB1 that is released from necrotic cells is shown 
to induce DCs maturation via an NF-κB pathway. A 
tumor-promoting role for NF-κB activation is also 
indicated in TAMs (tumor-associated macrophages) 
in mouse tumor model. Since IR induces cell death via 
apoptosis and/or necrosis, it is reasonably believed 
that IR helps to prime anti-tumor immunity via 
antigenic proteins released by cancer cells and 
increase antigen uptake by DCs, which enhances DC 
maturation. However, these results also implicate that 
due to huge effector gene profile affected by NF-κB 
regulation in tumor and normal cells in the ITME, 
NF-κB itself may not be an ideal immune target in 
cancer treatment to synchronize RT-mediated cancer 
treatment. NF-κB pathways may be used as a tool to 
identify specific tumor antigenic proteins especially 
the antigenic membrane proteins such as CD47 and 
HER2 (refer to below) as well as neoantigens that can 
be applied for the combined therapy of RT with TIT. 
Moreover, elucidation of the specific clusters of genes 
of NF-κB responsible for control of pro- and 
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anti-tumor immunity in both tumor and immune cells 
in the ITME will add significant insights on 
radiation-associated immune regulation in solid 
tumor. 
Radiation induced immune-targetable 
elements 
Radiation-induced tumor cell death has been 
shown to induce the release of tumor associated 
antigens and the “danger signals”, including HSPs, 
HMGB1, and calreticulin, which can induce DCs 
maturation and differentiation [72]. However, it is 
argued that although such released antigenic proteins 
may potentially prime and activate immune cells, 
they may not be highly effective if such antigenic 
proteins are not efficiently presented on the surface of 
therapy-surviving tumor cells. Therefore, 
radiation-induced antigenic proteins in the surviving 
tumor cells especially the highly tittering antigenic 
proteins from cancer stem cells or stem-like cancer 
cells in the recurrent and metastatic lesions need to be 
further elucidated. As discussed above, recent studies 
have revealed significant alterations on the surface of 
cells (including both tumor and tumor-related cells). 
The usefulness of such antigenic proteins termed as 
RAAPs in this review will depend on their unique 
feature of differentially expressed on tumor cells 
rather than normal cells in an irradiated solid tumor 
[73]. Further identification of this cluster of RAAPs in 
irradiated tumor microenvironment especially on the 
basis of individual tumors may improve the specific 
tumor targeting and increase ‘indirect killing’ effect of 
radiation. Below, we will summarize a short list of the 
radiation-induced antigenic proteins and cellular 
factors.  
HLA  
Human leukocyte antigen (HLA) is a 
well-studied complex of genes encoding the major 
histocompatibility complex (MHC) that locates on cell 
surface for fundamental immune regulation. MHC 
plays a key role in the acquired immune regulation to 
identify foreign molecules and defines 
histocompatibility. MHC is able to bind to antigens 
and displays them on the cell surface for recognition 
by the appropriate T-cells. MHC consists of two 
classes with a large scale of different alleles allowing 
them to be highly adaptive to varied epitopes. MHC 
class 1 (with subfamilies of classical ones-A, B, C and 
non-classical ones-E, F, G) present antigens from 
inside of cells (including self-antigens or integrated 
antigens of pathogens such as viruses), whereas, 
MHC class 2 (with subfamilies of DR, DP, and DQ) 
present antigens from outside of cells. All of the MHC 
molecules are sensitive to the genotoxic stress induced 
by radiation with either up- or down-regulating their 
expression [74]. In cancer cells, MHC expression is 
generally down-regulated which is related to the 
ability of escaping from immune surveillance. The 
Class 1 molecules of MHC are reduced in tumor cells 
[75, 76] which reduces the chance to be recognized by 
active immune cells. This class is known to be induced 
by IR via radiation induced interferon (IFN type 1) 
release. However, the molecules in MHC Class 2 
along with its subfamilies show different radiation 
responses [77, 78].  
HLA-G, from the non-classical category of MHC 
class 1, is upregulated in cancer cells [79] and 
suppressed via radiation due to its sensitivity to RT, 
indicating a potential biomarker and target for tumor 
imaging and radiosensitization [80]. HLA-G differs 
from the classical groups of HLA based on its function 
of suppressing immune cells via binding their Ig-like 
receptors (such as ILT-4 ILT-2, KIR2DL4 to 
monocytes, B and T cells and natural killers). 
Similarly, HLA-E is also found to be enhanced in 
cancer cells and reduced under radiation [80]. 
Gallegos et al speculated that this downregulation of 
HLA-E is a secondary event to the downregulation of 
HLA-G which indicates that HLA-G may be required 
for stabilizing HLA-E [74]. In addition, HLA-G 
enhances the apoptosis of immune cells and down 
regulates chemokine receptors on immune effector 
cells. Therefore radiation mediated down-regulation 
of these HLAs in cancer cells are potential immune 
regulators for enhancing the functions of immune 
cells in the ITME.  
Immune checkpoint proteins 
CTLA-4: CTLA-4 (cytotoxic T-lymphocyte- 
associated protein 4), a member of the 
immunoglobulin superfamily, has a critical function 
in tumorigenesis process and CTLA-4 blockade 
combined with RT is shown to enhance survival in a 
murine glioma model [81] and in human cancers [82, 
83]. The potential synergy between RT and TIT with 
anti-CTLA-4 is recently well-summarized [83, 84]. 
CTLA-4 is predominantly expressed on Treg cells [85] 
and thus is termed as immune checkpoint inhibitors 
together with PD-1/PD-L1. Classically, T cells are 
activated via APC presentation with MHC as a 
primary signal and CD80/86 as a secondary 
costimulatory signal. These surface molecules are 
known to be interacted with TCRs and CD28 on T 
cells thus activating the immune response. However, 
increased expression of CTLA-4 is shown to compete 
with CD28 [86, 87]. Because CTLA-4 has greater 
affinity than CD28, its high expression on cancer cells 
inhibits immune effector cells activation via increased 
CTLA4-CD80/86 binding. In addition, CTLA-4 is 
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known to regulate integrin dependent motility of 
immune active cells [88] and prevent T cells to form 
long term interactions with APC [89]. This inhibitory 
environment may push the immune modulatory cells 
to release inhibitory molecules such as TGF-β [90] or 
IL-10 [91], escalating the immune suppressor 
microenvironment. When such effect on Treg cells is 
blocked, activation of T cells and diversity in TCR 
repertoire is enhanced [92].  
PD-1/PD-L1: The other radiation-associated 
immune key checkpoint proteins are PD-1 and PD-L1 
which act in later phase of immune suppression 
process (compared to CTLA-4) [93] and are important 
for peripheral tolerance. Their interaction causes 
inhibition of secretion of TNFα and IFN-ɣ, and 
activation of TGF-β secretion [94]. The final effect is 
expectedly in favor of immunosuppression. 
Additionally, PD-1 /PD-L1 is thought to have a role in 
‘adaptive suppression’ of T cell activation [95]. Like 
CTLA-4, it pushes T cells to reduce their TCR 
expression, to reprogram their methylation level of 
their genome, to become allergic to locally expressed 
antigens, and to incline to apoptosis as well in in T cell 
exhaustion [96]. More interestingly, Prima et al 
hypothesized that COX2-mediated PGE2 production 
pathway might modulate PD-L1 expression on 
myeloid derived suppressor cells. To prove that, they 
utilized pharmacologic inhibitors for COX2 and 
showed a reduced production of PGE2 together with 
reduced expression of PD-L1 [97]. 
Blocking of these immune checkpoint proteins 
aims to ‘wake up’ the cytotoxic cells and abolish their 
exhaustion. It also causes the clonal expansion of T 
cells that will be expanded to a diversity of TCR 
repertoire [92]. Thus, RT with anti-PD-1/PD-L1 
strategy is superior to single therapy since blocking 
therapies increases the power of ‘in situ vaccine effect’ 
therefore it creates more antigenic stimulation related 
cytotoxicity [84]. It is thus believed that IR-mediated 
cell death augments tumor-specific immunity. Deng 
et al revealed that IR combined with anti-PD-L1 
enhanced T cell-mediated tumor cytotoxicity by 
enhancing the interplay IR and inhibition of 
PD-L1/PD-1 [98]. Hu et al reviewed the overall 
response rate of immune therapy in breast cancers 
(19%) and the combination therapy significantly 
enhanced the response rate [99]. Pike et al 
investigated the overall survival outcomes for several 
types of cancers after combination therapy with PD-1 
inhibition plus RT and their results indicate a 
prolonged survival compared to traditional single 
therapies [100]. Several questions remain to be 
addressed in such combined therapies, which include 
the dynamics of PD-1/PD-L1 expression in irradiated 
tumor cells and immune cells, and the timing the RT 
that can eliminate a bulk of tumor cells lack of PD-1 
expression before anti-PD-1/PD-L1 therapy.  
CD47: In addition to above checkpoint proteins, 
CD47 (cluster of differentiation 47), is becoming one 
of key immune targets in cancer immunotherapy. 
CD47 is an anti-phagocytic signal in cancer cells to 
evade from TAMs for immune escaping [101]. 
Originally identified in β3 integrin-mediated 
signaling on leukocytes [102], CD47 interacts with 
thrombospondin-1, signal regulatory protein-alpha 
(SIRPα), leading to a different cellular functions 
[103-109]. The interaction between CD47 on tumor 
cells and SIRP-α on immune effector cells generates a 
"don't eat me" signal to suppress the immune 
response [110]. CD47 ligates SIRPα expressed on 
macrophages and DCs and initiates a 
dephosphorylation cascade to inhibit phagocytosis 
[111-113]. Consistently, CD47-/- cells are removed fast 
when they are adoptively transferred to the 
congeneric wild-type mice [114]. Jaiswal et al and 
Majeti et al showed that CD47 in leukemic stem cells 
(LSCs) can inhibit macrophage activity that is linked 
with the growth advantage of LSCs [115, 116].  
CD47 is widely expressed at low level in normal 
tissues and highly expressed on multiple tumors, 
including hematological and solid cancers [117-121]. 
Considering the important inhibitory role of CD47 in 
phagocytosis of tumor cells, it is thus viewed as one of 
potential immune target in anti-cancer 
immunotherapy. Initially, most studies focused on the 
direct killing effect of anti-human CD47 [122-124]. 
Subsequently, its indirect functions in regulating 
phagocytosis or tumor death were noticed. Recently, 
CD11b activation which is necessary for macrophage 
activation for tumor cell phagocytosis is found to be 
actively involved in anti-tumor innate immunity 
[125]. Combining CD47 blockade with irradiation 
significantly affected tumor growth and enhanced 
tumor sensitivity to irradiation in syngeneic 
immunocompetent mouse [126]. Transcription of 
CD47 can be enhanced by IR [127] and inhibition of 
CD47 signaling conferred a survival advantage to 
irradiated normal tissue via promoting viability and 
proliferative capacity in an autophagy-dependent 
manner [128]. Liu et al found that the therapeutic 
effects of CD47 blockage depended on DCs but not 
macrophage cross-priming of T cell responses in 
syngeneic immunocompetent mouse. Chemotherapy 
might impact the efficacy of anti-CD47 treatment by 
suppressing T-cell memory response [129]. Currently, 
about eight phase I clinical trials and two phase II 
clinical trials are evaluating the effects by blocking 
CD47-SIRPα pathway in various cancer types. 
Combined treatments of humanized monoclonal 
anti-CD47 antibody Hu5F9-G4 and chemotherapy 
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were administered to patients with solid tumors that 
are not fit for conventional therapies [130, 131]. 
However, the clinical responses could not be 
confirmed probably due to the small numbers of 
patients recruited [132]. 
The enhanced expression of CD47 in the tumor 
microenvironment could severely hamper tumor 
radiosensitivity [126, 133]. Betancur et al showed that 
CD47 were remarkably enhanced in HER2 positive 
breast cancer HCC1954 and luminal A MCF7. NF-κB 
and PPARα were identified as two transcription 
factors that bound with super-enhancer of CD47 and 
regulated protein expression [134]. Our lab 
discovered a co-expression pattern of CD47 and HER2 
in a series of radioresistant breast cancer cell lines that 
survive from fractionated doses of IR [135]. Since both 
promoters of CD47 and HER2 contain NF-κB binding 
motif, a possible co-expression pattern between these 
two RAAPs is proposed (Fig. 3, and unpublished 
data). More recently CD47 was found have another 
co-expression model in breast cancer as well. Cook et 
al revealed that glucose regulated protein 78 (GRP78) 
may correlate with the expression of CD47. Thus, 
targeting GRP78 significantly altered CD47 
expression, indicating UPR involvement in CD47 
regulation [136, 137]. These two RT-induced 
membrane proteins should be considered as the 
candidates for dual immune targets in the RT 
combined therapy.  
Other immune regulators 
A large scale of molecules can alter their 
expressions under radiation and is assumed to be 
involved in immune regulation (a selected list is 
shown in Table 1). Most of such molecules are 
derived from ER with the accelerated production 
under IR and they directly modulate cell survival. 
Below, we list some of stress-associated molecules as 
well as non-ER derived ‘danger signal’ molecules that 
show potential targetable application.  
HMGB1: HMGB1 (25 kDa molecular weight) is 
an intra-nuclear protein regulating gene transcription 
by binding chromosomal proteins or interacting with 
several transcription factors [153]. Although HMGB1 
physiologically enhances immune activation and 
motility through TLR4 activation [154], several 
studies show that HMGB1 is linked with poor 
prognosis probably due to its interaction with 
myeloid differentiation factor 88 and TLR4 [154-156]. 
He et al found that HMGB1 which helped tumor cell 
proliferation was released into the medium in Hela, 
 
 
Figure 3. Two RAAPs, CD47 and HER2, regulated by NF-κB in radioresistant cells. (A) SIRP-α is an inhibitory receptor expressed on immune cells including 
macrophages, DCs and neutrophils. SIRP-α binds CD47 (generating do-not-eat me signaling on tumor cells) to recruit inhibitory molecules, such as SHP-1 and SHP-2, preventing 
the activation of immune myeloid cells, in particular macrophages, so to shield tumor cells from macrophage-mediated phagocytosis. (B) Both HER2 and CD47 are RAAPs 
inducible in breast cancer cells by radiation via NF-κB-mediated transactivation. CD47 provides the immune-shielding capacity to escape the immune surveillance which together 
with HER2-mediated intrinsic pro-survival networks, contributes to the overall tumor aggressive phenotype and radioresistance. Therefore, immune blockage of CD47 and 
HER2 may be able to maximize macrophage-mediated phagocytosis on tumor cells that survived RT. 
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HT29, HT116 cells treated with 10 Gy IR [157]. 
However, the priming function of induced HMGB1 is 
suggested to translocate to cytosol after acetylation or 
phosphorylation and secreted to extracellular 
compartment in passive or active way. HMGB1 
secretion is induced by interferons (IFNs) in 
acetylated or phosphorylated type to extracellular 
compartment. HMGB1 can be released from active 
immune cells. For instance, activated DCs secrete 
HMGB1 before maturation and the extracellular 
HMGB1 induces a feedback signaling for the 
maturation of DCs and activation of T cells. As to 
passively secretion, it is released by dead cells or 
dying cells, such as RT induced cell death. It has been 
shown that HMGB1 level is enhanced in the tumor 
microenvironments with increased tumor antigen– 
specific T-cells in patients with esophageal cancer 
treated by chemoradiotherapy [138] and the release of 
HMGB1 is proportional to the radiation doses 
delivered by carbon-ion beam irradiation [139].  
 
Table 1. Selected RT-related immune regulators induced by 
radiation  
Molecule Function Immune 
and/or tumor 
cells 
Behavior under 
IR 
References 
HMGB1 Danger signal, 
enhancing tumor 
immunogenicity 
both immune 
and tumor 
cells 
Inducible by IR [138, 139] 
GRP78 Immune regulation 
and signal 
transduction 
both immune 
and tumor 
cells 
Radioresistance [140] 
HLA Reduced expression 
to escape (except 
HLA-G and HLA-E) 
Immune cells Induced [40, 141, 
142] 
CTLA-4 Immunosuppression activated T 
cells 
Induced under 
low doses, 
diminished under 
high doses 
[143-145] 
PD-1/PD-L
1 
Immunosuppression T cells/tumor 
cells 
Induced [98, 146, 
147] 
CD47 “Don’t eat me” 
signaling  
 tumor cells Induced (in 
survived cells) 
[109, 148] 
Ox40 Support for immune 
effector cells and 
APC  
 immune cells Induced [149-152] 
 
GRP78 (glucose regulated protein 78, or termed 
immunoglobulin heavy chain binding protein, BIP): a 
member of heat-shock protein 70 (HSP70) family 
located in endoplasmic reticulum (ER) lumen, plays a 
key role in the UPR and is linked with tumor 
resistance and prognosis [158, 159]. Although known 
in regulating protein folding stress [160], GRP78 is 
shown to be involved in a wide array of stress 
conditions including glucose depletion, low oxygen 
levels, high levels of oxidant molecules [161] as well 
as in DNA-damage response [162]. GRP78 is able to 
regulate lipid metabolism related to drug sensitivity 
and anti-tumor immunity in breast cancer [137]. 
GRP78 and MTJ-1 a transmembrane protein are 
identified in the macrophage plasma membrane 
lysates, indicating GRP78 can be relocated to cell 
surface to participate in immune regulation and signal 
transduction [163, 164]. GRP78 is shown to be 
involved in hepatitis C virus (HCV) replication and 
Toll-like receptor-3 (TLR3)-initiated antiviral state 
[165]. The safety of TIT using anti-GRP78 antibody 
PAT-SM6 has been tested in mouse model for 
treatment of relapsed or refractory multiple myeloma 
[166]. Although such tests should be further 
evaluated, TIT with GRP78 antibody was 
demonstrated to inhibit CD47 and enhance tumor 
infiltration of immune cells to increase an anti-tumor 
microenvironment. The correlations between GRP78 
and radiation is demonstrated by the observation that 
expression of GRP78 is related to the radiosensitivity 
of brain endothelial cells [140] and expression of 
GRP78 is enhanced in breast cancer stem cells (BCSCs) 
and responsible for self-renewal and radioresistance 
of BCSCs [167]. TIT with anti-GRP78 antibody 
showed extraordinary inhibition on the aggressive 
phenotype of GBM and NSCLC cells due to inhibition 
of PI3K/Akt/mTOR pathway, and tumor inhibition 
was enhanced by RT combined with TIT of GRP78 in 
tumor model of NSCLC and GBM [168].  
CD134 (Ox40): This molecule, mainly expressed 
on activated CD4 and CD8 T cells, supports the 
activation of immune effector and antigen presenting 
cells and promotes them to elongate their survival 
time and release cytokine [169]. Additionally CD134 
suppresses the differentiation and activity of Treg 
[170]. Moran et al arranged series of experiments by 
using both CD134 agonists and antagonists plus with 
anti-immune checkpoint protein antibodies. The 
findings were encouraging for the further clinical 
usage of CD134 agonists because of its significant 
anticancer, pro-immune effects [171]. Combination of 
CD134 with radiation in lung cancer model resulted in 
an overall survival rate of 80% at 100 days compared 
to 0% in mice treated with either modality alone [172]. 
Similarly, surgical removal of 10-14 day sarcoma 
resulted in 50% local tumor recurrence whereas 
anti-CD134 delivered at the time of the operation 
eliminated local recurrence in 100% of mice. In 
addition anti-CD134 with surgery and radiation led to 
a survival rate of 50% at 70 days [173]. These two 
studies indicate that CD134 is a promising immune 
target and anti-CD134 combined with RT has the 
priority for clinical trials.  
TLRs: TLRs (toll-like receptors) are both cytosolic 
and membranous molecules which recognize 
pathogens by their pathogen associated molecular 
patterns and danger signals released from damaged 
cells. Due to their unique capacity of regulating the 
immune cascade in pro-inflammatory response, their 
potential application in TIT has been suggested [174] 
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as well as in combined therapy with RT [175, 176]. 
Accumulating preclinical evidence showed that 
agonists of TLRs, especially TLR3, 4, 7/8 and 9 
agonists, efficiently promote tumor-targeting immune 
responses initiated by anticancer immunotherapy. By 
providing essential requirements for stimulating 
innate and adaptive immunity as well as their effects 
on the tumor microenvironment, local application of 
TLR agonist as single agent exhibited effectively to 
eradicate tumors. There are two FDA-approved TLR 
agonists used as cancer monotherapy, bacillus 
Calmette-Guerin (BCG) and imiquimod. Apetoh et al 
reported that breast cancer patients with a TLR4 
loss-of-function allele relapse more quickly after 
radio- or chemo-therapy than those carrying the 
normal TLR4 allele. Further studies illustrated that 
activation of DCs during radio- or chemo- therapy 
required TLR4-mediated signaling [177]. Intravenous 
administration of the TLR7 agonist, R848 with RT, can 
inhibit T-and B-cell lymphoma in animal model; and 
led to a tumor-specific memory which is believed to 
prevent tumor recurrence [178].  
CRT: CRT (Calreticulin), a danger-sensor protein 
derived from endoplasmic reticulum, is able to 
translocate to the cell membrane after radiation where 
it generates "eat me" signals for tumor associated 
macrophages and lymphocytes [30, 179]. CRT viewed 
as an immunogenic signature associated with 
low-dose radiation should be categorized in the 
cluster of RAAPs and can interact with APCs to 
support IR induced ICD [136]. Surface expression of 
CRT was enhanced by radiation in an array of human 
cancer cells including prostate, breast, and lung [29] to 
promote APCs and T cell-mediated tumor cell killing 
[180].  
Other radiation related immune regulators  
Different non-immune and immune cells are 
present in irradiated solid tumors; some are thought 
to be pro-cancer like Treg, M2 macrophages, myeloid 
derived suppressor cells, neutrophils (N2 type), 
basophils, B lymphocytes, mast cells and some others 
on the contrary such as M1 macrophages, antigen 
presenting cells (DCs), CD8+ T lymphocytes or natural 
killer cells. Most importantly, these immune active 
cells are able to communicate and cooperate in the 
ITME to release cytokines and even non-coding 
transferrable genome parts [181]. Some of such 
cellular and non-cellular factors are described below. 
Extracellular matrix (ECM): ECM plays a key role 
in intercellular communication, sequestration of 
various factors, cellular adhesion and migration. As 
content, it has various types of proteins (collagen, 
elastin, laminin etc.), proteoglycans (keratin sulfate, 
heparin sulfate etc.) and liquid. Collagen and 
fibronectin are known to be related to tissue strength 
while proteoglycans support the sequestration of 
growth factors and cytokine providing [182, 183]. To 
be specific to cancer, extracellular matrix is showed to 
create a scaffold which guides tumor cells in their 
migration process and chemotaxis [184]. Moreover, 
cross-linking of proteins in ECM is surprisingly 
showed to support tumor cells to invade their local 
environment easier [185]. It was also projected by 
recent studies that ECM affected anti-tumor therapy 
efficacy by its interstitial fluid pressure [186], 
desmoplastic stroma and tissue rigidity [187].  
With local tumor RT, ECM can be remodeled in 
various ways, actually in favor of pro-tumor forces 
[188] which is believed to link with DNA damage, cell 
death and hypoxia [189, 190] as well as different 
factors released (such as VEGF, CSF-1, SDF-1 etc.) 
from both local host cells and tumor cells. These 
factors may attract various cells like TAMs or CAFs 
which have the capability to alter the 
microenvironment matrix by their products and even 
with their own cellular structures. Hypoxia, on the 
other hand causes acidification in stroma (whether it 
is induced by IR or not) due to accumulation of lactic 
acid released from cancer cells under 
highly-glycolytic conditions. Although it is unclear 
low pH status could be a unflavored factor for 
priming immune system, low pH is shown to alter 
cellular behaviors such as alteration of transcription 
factor expressions or increased invasiveness and 
migration [191]. Since HIF1 (hypoxia induced factor 1) 
is a well-defined activator of VEGF [192, 193], HIF1 
may shape tumor vascular support for survival and 
RT-resistance. These tumor associated vessels showed 
enhanced permeability with increased turbulent flow 
and increased numbers of pericytes [194] that can 
enhance tumor invasion/metastasis via reduction of 
P- and E-selectin, V-CAM, I-CAM, which are related 
to binding and homing for immune cells. Therefore, 
pericytes could be a potential target to enhance 
immune response under RT.  
Tumor cells are able to adhere to structural 
components of ECM leading to enhancement of 
cellular polarity and EMT (epithelial-mesenchymal 
transformation). This might be due to interaction of 
collagen, fibrin and/or laminin with integrin on the 
cell membrane via pathways such as FAK, 
PI3K/Akt/Stat3 and NF-κB [195, 196]. These all 
molecules along with their capability to cellular 
polarization may allow tumor cells to be 
apoptosis-resistant to chemotherapy and 
radiotherapy [183, 197]. Another way that ECM may 
cause anti-tumor therapy resistance is extracellular 
vehicles (EVs) such as the case in endothelial-derived 
EVs via noncoding RNA activators for Stat1 and/or 
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decoy for antibody treatment [198]. Such EVs could be 
potential immune targets to block tumor acquired 
radioresistance.  
DNA exonuclease Trex1: The TREX1 gene in 
mammalian cells encodes a dominant DNA 
exonuclease TREX1 enzyme that functions to degrade 
DNA [199, 200]. Mutations in the TREX1 gene are 
linked with a group of autoimmune diseases [201]. 
The DNA fragments accumulated in the cytoplasm of 
the irradiated cells can help cells to release 
interferon-β following activation of the DNA sensor 
cGAS and its downstream effector STING which is 
able to prime CD8+T cells for initiating the anti-tumor 
effect. Interestingly, TREX1 is identified to be 
inducible in irradiated cancer cells and the IR-induced 
TREX1 reduces the immunogenicity of irradiated 
cancer cells by degrading the DNA fragments 
accumulated in the cytoplasm [202, 203]. Such 
TREX1-mediated suppressive function on 
interferon-β has the potential of being an effective 
approach to regulate tumor immunogenicity in the 
combined therapy of RT and TIT.  
Cancer-associated fibroblasts (CAFs): Fibroblasts 
are the most common cell type in connective tissue 
and prevail in tumor tissues. They are normally found 
in a quiescent form with the potential to be 
transformed reversibly into their activated form 
under stress conditions such as wound healing. The 
CAFs are an irreversible state of fibroblasts found in 
tumor microenvironment and linked to several 
actions in tumor progression. A noteworthy skill of 
CAFs is that they are extremely resistant to 
radiotherapy [204]. The CAFs are believed to be the 
sufficient source of VEGF-α as well as other growth 
factors and extracellular matrix proteins to support 
reorganization and vascularization of tumor 
microenvironment [205, 206]. The CAFs also have 
pro-inflammatory characteristics [207] and are found 
to interact with local tumor cells and immune cells.  
The communication between tumor cells and 
CAFs also promotes the release of TGF-α that is able 
to remodel the microenvironment in favor of invasion 
and metastasis [208]. However tumor cells not only 
crosstalk with CAFs or APCs but also communicate 
with TAMs as well. This cross-talking is carried out 
with several different signaling pathways such as 
EGF, CSF-1, and Wnt [209]. And this often concludes 
with increased release of proteases like cathepsin 
[210] to promote further invasion and progression. 
Another combination in this crosstalk concept is 
realized with endothelial vesicles which again 
provide further organization and might play role in 
APC recruitment [211]. However the studies to prove 
the importance of CAFs and their crosstalk model 
revealed controversial findings. Some studies indicate 
increased aggressiveness in depleted stroma [212] 
while the others show a togetherness of low stromal 
index and better prognosis via improved drug 
delivery. 
Other active immune cells 
Macrophages are one of the main immune active 
cells involved in almost all inflammatory situations 
including ITME. Macrophages either promote 
inflammation and chaos (M1 macrophages) or push 
cells to act for tissue healing and fibrosis in the 
affected area (M2 macrophages).TAMs are found to 
be recruited to tumor microenvironment via CCL2 
[213, 214]. The chemokine CCL2 (also termed 
monocyte chemoattractant molecule–1, MCP-1) can 
recruit CCR2-expressing monocytes to tumor 
microenvironment where the monocytes are able to 
differentiate into TAMs and dendritic cells [215, 216]. 
Since these 2 subtypes of macrophages are 
functionally different, their products and activated 
signaling pathways are varied. Via NF-ĸB, STAT11 
and IRF [217, 218] activator signals, M1s uses CXCL9 
and CXCL10 to recruit immune effector cells. In 
contrast, M2s secrete CCL5, CCL17, CCL20, CCL22 to 
recruit immune modulator cells like Tregs via IRF4, 
STAT6, c-Myc, PRAR signaling [219]. Although the 
functions of TAMs on tumor cells are still in debate, 
increasing results support the pro-tumor effects. Via 
NF-κB signaling, TAMs promote EMT [220] (a 
well-known radioresistant state of cells), local 
invasion, intra- and extravasation (by 
neovascularization) [221, 222], seeding and growth at 
distant sides; together indicating their relationship 
with increased metastasis risk. However, in addition 
above mentioned TIT via anti-CD47 which enhances 
macrophage-mediated phagocytosis on tumor cells, 
macrophages in the metastatic tumors are found to 
secrete granulin that activates local myofibroblasts 
and leads to fibrosis via periostin secretion [223-225]. 
This mechanism is thought to be a protective role of 
organism to prevent further invasions and metastasis.  
In addition, TAMs are capable of recruiting (via 
CCL5, CCL20, CCL22) and activating Treg (via IL-10 
[226] for TGF-β production [84] and inducing the 
checkpoint proteins and ARG1 [227] and NOS to 
suppress effector T cells, which is thought to promote 
immune suppression in tumor microenvironment 
[228, 229]. Pinto et al investigated the relationship 
between TAMs and cancer cells in co-cultures of 
different cancer cell lines. Although their results 
showed different responses for different cancer cell 
lines, the overall output from their study was that 
TAMs were definitely in contact with cancer cells and 
they even might regulate metabolism, gene 
expression and cytokine production under IR and 
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overall radiation response of cancer cells [230]. 
Fortunately, IR shifts the pro-tumor effects 
predominance to anti-tumor side. IR pushes the 
transformation M2 to M1 [231] and production of NO 
[232]. However the alone application of IR generally is 
not sufficient to overcome this strong predominance. 
That’s one of the reasons why IR becomes much more 
effective when combined with immune-therapeutics. 
Dendritic cells: Tumor infiltration of DCs and 
several other immune effector cells is carried out via 
several cytokines such as CXCL16, TNFα, IL-1β, IL-6 
secreted by IR induction of tumor cells [233]. 
Attracted APCs, however, might play a little different 
role on the contrary of generally known antigen 
presentation process. Current studies indicated that 
irradiated APCs play an immune suppressor role via 
down regulating its immune activator (T cell 
polarizator) IL-12 and IL-23 cytokines. Moreover to 
this, in tumor microenvironment, the communication 
between CAFs and DCs (like COX2 dependent PGE2, 
released from fibroblasts) provides DCs to maintain 
their immune suppressor activity through promoting 
further IL-23 synthesis despite IR application. In the 
presence of IL-1β and TNFα, IL-23 is found to be a T 
cell polarizing factor that accelerates CD4+ cells to 
transform into Th17 cells resulting in an immune 
modulator environment. In addition, the DCs are 
showed to maintain their presence and abilities even 
under the genotoxic stress of IR (with some 
modifications), indicating their strong adaption under 
IR condition [204]. Further elucidation will be in need 
on the mechanistic insights of cross-talk between DCs 
and tumor cells, especially the communication 
between DCs and radiation-surviving tumor cells.  
Potential clinic trials 
Accumulating clinical and experimental data 
support a potential synergy of RT with TIT [5, 234]. 
Radiation induced or enhanced concomitant 
immunity on different tumors has been tested in 
animal models [4, 235]. The “optimal RT doses” to 
enhance tumor immunogenicity is to be further 
optimized especially based on different tumors and 
individual patients. Dewan et al observed that RT 
with fractionated doses combined with anti-CTLA4 
treatment not only delayed the growth of primary 
tumors but induced abscopal effect with enhanced 
CD8+ T cells in mouse breast and colon cancer models 
[144]. Local RT combined with immune targeting by 
anti-PD-1 or anti-PD-L1 antibody also demonstrate 
the benefits in activation of the cytotoxic T-cells with 
improved tumor control and animal survival [98]. 
Surface GRP78 is closely related to tumor 
radiotherapy response and cancer recurrence. 
Targeting surface GRP78 by peptide or antibody 
strengthens the reaction of tumor to radiotherapy 
[168, 236]. In addition, the IFNγ produced by CD8+ T 
cells is shown to enhance PD-L1 expression in tumor 
cells after RT with fractionated ionizing radiation 
(FIR) [234, 237]. Enhanced tumor responses and 
survival benefits are also detected in mouse with 
intracranial gliomas treated by anti-PD-1 combined 
with stereotactic RT [146]. All of these animal models 
have generated supportive data for clinical trials of RT 
combined with TIT.  
In a pioneering clinical trial, local RT was 
conducted with the regimen of 35 Gy in 10 fractions to 
one metastatic site along with concurrent GM-CSF 
(125 μg/ml subcutaneously injected daily for 2 weeks, 
starting during the second week of radiotherapy). 
This trail identified the abscopal effects in 11 of 41 
patients. The mortality rate in patients absent of 
abscopal effects was more than twice than patients 
with it [238]. In the current era of PD1/PD-L1, 
increasing reports have indicated the encouraging 
synergy of RT with checkpoint blockade [239]. Many 
such trials are underway and data are going to be 
accumulated soon [240]. However, it was found that 
RT/anti-PD-1 therapy was effective only on RT-naïve 
tumors and anti-PD-1 did not generate anti-tumor 
efficacy in RT-relapsed tumors [241], indicating 
additional factors against systematic immune 
surveillance could be induced in RT-surviving tumor 
such as RT-resistant cancer stem cells, which is to be 
further elucidated.  
The ideal situation is that we could define a RT 
regimen that augments the immunogenicity of tumor 
cells without activation of tumor immune suppressing 
factors such as PD-1/PD-L1 and CD47 in ITME. 
Optimization of such RT doses and selection of an 
effective immune target for TIT could be a challenge, 
especially with the variations in RT responses to 
individual TME. However, with the twilight of more 
clinical studies being evaluated, increasing numbers 
of studies and clinical trials have demonstrated that 
hypo-fractionated regimen of RT before TIT could 
enhance the efficacy of tumor control [144, 234] with 
increased TAA (tumor-associated antigen) 
production, thus augmenting immune stimulation. 
However there are some obstacles and controversial 
speculations about the timing for RT delivery. It is 
suggested that the effectiveness of RT may be limited 
if it is applied before TIT since the predominance of 
immune suppressive forces in the untreated TME may 
eliminate appropriate induction of TAAs [214]. On the 
other hand, if it is applied after immune therapy, it 
might destroy the local immune effective cells which 
are recruited by applied immune therapy. Although 
facing such dilemma, the common consensus 
signposts that the hypo-fractionated regimen should 
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be strong enough to induce tumor immunity but not 
to damage local immune cells [242, 243]. Regimens 
such as 5Gy x 4, 8 Gy x 3 are effective approaches 
applied with the immune checkpoint blockade [144]. 
Among the immune targets in clinical trials that can 
be potentially combined with RT, immune checkpoint 
protein inhibitors are currently popularly studied. 
Other immune effectors against tumor cells such as 
soluble immune activator including interleukins like 
IL-3, immune cells colony stimulant factors like 
GM-CSF, inducers and growth factors for specific cell 
types like Flt3-L for DCs [244] are also being 
investigated. 
Conclusion and Perspectives 
With the renaissance of targeted immunotherapy 
especially checkpoint inhibitors being approved by 
FDA, antibody-based ICBs such as atni-CTLA-4 and 
anti-PD1/PD-L1 have created impressive clinical 
impacts on treatment of an array of human cancers 
including lung cancer, melanoma, glioblastoma and 
other solid tumors. These exciting results encouraged 
further investigations on potential synergy of TIT 
with RT. In Clinicaltrials.gov, increasing trials have 
been registered: “CTLA-4/radiotherapy” (67 studies); 
“PD-1/radiotherapy” (182 studies); 
“PD-L1/radiotherapy” (186 studies); “CD47/ 
radiotherapy” (1 study). These primary trials reveal 
that combination of RT with TIT may improve clinical 
outcomes compared with either treatment alone. For 
instance, in treatment of melanoma patients with 
brain metastases, the 3-year survival rate for patients 
treated with ipilimumab (targeting CTLA-4) and 
stereotactic radiosurgery was 50% while for patients 
without treatment of ipilimumab was 39% [245]. 
Prolonged survival and metastases control were also 
observed in patients with PD1-targeting inhibitor 
OPDIVO combined with RT [147]. Moreover, overall 
survival in the combined treatment group (RT 
combined ipilimumab or anti-PD-1) was reported to 
be superior to single treatment group [246, 247]. As 
such, in the eve of a coming era of combined 
modalities of RT with increasing immune targets, a 
potential significant enhancement in cancer control 
could be expected.  
However, although RT/TIT combined therapy is 
promising, current clinical studies are mainly limited 
to CTLA-4 or PD-1 targeting inhibitors. The fact that 
many patients show no response to combined 
treatment and some responders develop acquired 
resistance after initial response indicating that the 
RAAPs discussed in this review need to be explored. 
Most importantly, the mechanistic insights of 
radiation induced anti-tumor response (priming 
function) requires further elucidated. Elements 
induced in ITME including CXCL16, CTLA-4, CD47, 
HER2, PD-1 and PD-L1 in line with many other 
potential immune suppressors may enhance the 
immune-escaping capacity of tumor cells, which may 
severally compromise the radiation-induced priming 
function. The induced immune suppressors on the 
other hand provide targetable molecules for TIT or for 
combined RT/TIT. The potential clinical benefits 
should be expected from further targeting these 
different immune-associated elements to increase the 
tumor immunogenicity and the priming function. The 
ideal situation would be that an RT regimen could be 
optimized to enhance the priming function rather 
than immune suppressive factor in ITEM and thus 
will benefit with TIT. For example, the 
radiation-surviving tumor cells including cancer stem 
cells that may be effectively eliminated by TIT 
following RT if such fraction of tumor cells express 
the proper immunologic molecules on the cell surface 
such as PD-1/PD-L1 [248]. More experimental results 
and clinical data are expected to reveal additional new 
insights of immune regulators in the ITME. These 
results will be necessary to deepen our understanding 
of radiation-associated immune regulation and guide 
to invent more effective targets in RT combined with 
targeted immunotherapy.  
Acknowledgments 
We apologize to the authors whose publications 
could not be included in this review due to limited 
space. The authors thank Dr. Mansoor Ahmed at NCI, 
NIH and Dr. Andrew Vaughan at UC Davis Cancer 
Center for their critical reviewing the manuscript. 
This work was supported by National Cancer 
Institute Grants RO1 CA213830 (to JJL). The costs of 
publication of this article were defrayed in part by the 
payment of page charges. This article must therefore 
be hereby marked advertisement in accordance with 
18 U. S. C. Section 1734 solely to indicate this fact. 
Author contributions 
O.M.O., and J.J.L. conceived the idea for the 
review. O.M.O., L.Z., and J.J.L. wrote the manuscript. 
L.Z. generated the figure panels. L.Z., and J.J.L edited 
the final version of the manuscript.  
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1. Schaue D, McBride WH. Opportunities and challenges of radiotherapy for 
treating cancer. Nat Rev Clin Oncol. 2015;12:527-540. 
2. Weichselbaum RR,Liang H,Deng L, Fu YX. Radiotherapy and 
immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14:365-379. 
 Theranostics 2019, Vol. 9, Issue 5 
 
 
http://www.thno.org 
1227 
3. Bernstein MB,Krishnan S,Hodge JW, Chang JY. Immunotherapy and 
stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin 
Oncol. 2016;13:516-524. 
4. Barker HE,Paget JT,Khan AA, Harrington KJ. The tumour microenvironment 
after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 
2015;15:409-425. 
5. Marciscano AE, Walker JM, McGee HM, Kim MM, Kunos CA, Monjazeb AM, 
et al. Incorporating Radiation Oncology into Immunotherapy: proceedings 
from the ASTRO-SITC-NCI immunotherapy workshop. J Immunother Cancer. 
2018;6:6. 
6. Diegeler S, Hellweg CE. Intercellular Communication of Tumor Cells and 
Immune Cells after Exposure to Different Ionizing Radiation Qualities. Front 
Immunol. 2017;8:664. 
7. Demaria S,Coleman CN, Formenti SC. Radiotherapy: Changing the Game in 
Immunotherapy. Trends Cancer. 2016;2:286-294. 
8. Ahmed KM, Li JJ. NF-kappa B-mediated adaptive resistance to ionizing 
radiation. Free Radic Biol Med. 2008;44:1-13. 
9. Wu ZH,Shi Y,Tibbetts RS, Miyamoto S. Molecular linkage between the kinase 
ATM and NF-kappaB signaling in response to genotoxic stimuli. Science. 
2006;311:1141-1146. 
10. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, 
et al. Radiation and dual checkpoint blockade activate non-redundant 
immune mechanisms in cancer. Nature. 2015;520:373-377. 
11. Formenti SC, Demaria S. Combining radiotherapy and cancer 
immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105:256-265. 
12. Halvorsen AR, Helland A, Fleischer T, Haug KM, Grenaker Alnaes GI, Nebdal 
D, et al. Differential DNA methylation analysis of breast cancer reveals the 
impact of immune signaling in radiation therapy. Int J Cancer. 
2014;135:2085-2095. 
13. Ludgate CM. Optimizing cancer treatments to induce an acute immune 
response: radiation Abscopal effects, PAMPs, and DAMPs. Clin Cancer Res. 
2012;18:4522-4525. 
14. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. 
Immunologic correlates of the abscopal effect in a patient with melanoma. N 
Engl J Med. 2012;366:925-931. 
15. Bockel S,Antoni D,Deutsch E, Mornex F. [Immunotherapy and radiotherapy]. 
Cancer Radiother. 2017;21:244-255. 
16. Sharma A, Bode B, Wenger RH, Lehmann K, Sartori AA, Moch H, et al. 
gamma-Radiation promotes immunological recognition of cancer cells 
through increased expression of cancer-testis antigens in vitro and in vivo. 
PLoS One. 2011;6:e28217. 
17. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. 
Genomic amplification of a decoy receptor for Fas ligand in lung and colon 
cancer. Nature. 1998;396:699-703. 
18. Chiang CS, Fu SY, Wang SC, Yu CF, Chen FH, Lin CM, et al. Irradiation 
promotes an m2 macrophage phenotype in tumor hypoxia. Front Oncol. 
2012;2:89. 
19. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism 
and functions. Immunity. 2010;32:593-604. 
20. Teng F,Kong L,Meng X,Yang J, Yu J. Radiotherapy combined with immune 
checkpoint blockade immunotherapy: Achievements and challenges. Cancer 
Lett. 2015;365:23-29. 
21. Shiao SL,Ganesan AP,Rugo HS, Coussens LM. Immune microenvironments in 
solid tumors: new targets for therapy. Genes Dev. 2011;25:2559-2572. 
22. Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W, et al. Combining 
Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges 
and Future Directions. Front Pharmacol. 2018;9:185. 
23. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune 
evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer 
Biol. 2015;35 Suppl:S185-S198. 
24. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing 
radiation inhibition of distant untreated tumors (abscopal effect) is immune 
mediated. Int J Radiat Oncol Biol Phys. 2004;58:862-870. 
25. Kingsley DP. An interesting case of possible abscopal effect in malignant 
melanoma. Br J Radiol. 1975;48:863-866. 
26. Raventos A. An abscopal effect of x-ray upon mouse spleen weight. Radiat 
Res. 1954;1:381-387. 
27. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 
1953;26:234-241. 
28. Grass GD,Krishna N, Kim S. The immune mechanisms of abscopal effect in 
radiation therapy. Curr Probl Cancer. 2016;40:10-24. 
29. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. 
Radiation-induced immunogenic modulation of tumor enhances antigen 
processing and calreticulin exposure, resulting in enhanced T-cell killing. 
Oncotarget. 2014;5:403-416. 
30. Hu ZI,McArthur HL, Ho AY. The Abscopal Effect of Radiation Therapy: What 
Is It and How Can We Use It in Breast Cancer? Curr Breast Cancer Rep. 
2017;9:45-51. 
31. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, 
Erlandsson-Harris H, et al. High mobility group 1 protein (HMG-1) stimulates 
proinflammatory cytokine synthesis in human monocytes. J Exp Med. 
2000;192:565-570. 
32. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-Dependent 
Cytosolic DNA Sensing Promotes Radiation-Induced Type I 
Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. 
Immunity. 2014;41:843-852. 
33. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. Low-dose 
irradiation programs macrophage differentiation to an iNOS(+)/M1 
phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 
2013;24:589-602. 
34. Holzel M,Bovier A, Tuting T. Plasticity of tumour and immune cells: a source 
of heterogeneity and a cause for therapy resistance? Nat Rev Cancer. 
2013;13:365-376. 
35. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, et al. 
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and 
CTL adoptive immunotherapy. J Immunol. 2003;170:6338-6347. 
36. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. 
Sublethal irradiation of human tumor cells modulates phenotype resulting in 
enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64:7985-7994. 
37. Hallahan D,Kuchibhotla J, Wyble C. Cell adhesion molecules mediate 
radiation-induced leukocyte adhesion to the vascular endothelium. Cancer 
Res. 1996;56:5150-5155. 
38. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. 
Radiation-induced IFN-gamma production within the tumor 
microenvironment influences antitumor immunity. J Immunol. 
2008;180:3132-3139. 
39. Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, 
et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector 
T cells. J Immunol. 2008;181:3099-3107. 
40. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley 
EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I 
expression, and induces successful antitumor immunotherapy. J Exp Med. 
2006;203:1259-1271. 
41. Ruocco MG, Pilones KA, Kawashima N, Cammer M, Huang J, Babb JS, et al. 
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves 
antitumor effects. J Clin Invest. 2012;122:3718-3730. 
42. Reynders K,Illidge T,Siva S,Chang JY, De Ruysscher D. The abscopal effect of 
local radiotherapy: using immunotherapy to make a rare event clinically 
relevant. Cancer Treat Rev. 2015;41:503-510. 
43. Sun Z,Chen F,Meng F,Wei J, Liu B. MHC class II restricted neoantigen: A 
promising target in tumor immunotherapy. Cancer Lett. 2017;392:17-25. 
44. Sethuraman SN, Ranjan A. Neoantigen activation, protein translocation and 
targeted drug delivery in combination with radiotherapy. Ther Deliv. 
2016;7:377-385. 
45. Kim JY, Son YO, Park SW, Bae JH, Chung JS, Kim HH, et al. Increase of 
NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells 
by heat shock and ionizing radiation. Exp Mol Med. 2006;38:474-484. 
46. Marconi R,Strolin S,Bossi G, Strigari L. A meta-analysis of the abscopal effect 
in preclinical models: Is the biologically effective dose a relevant physical 
trigger? PLoS One. 2017;12:e0171559. 
47. Johnson CB, Jagsi R. The Promise of the Abscopal Effect and the Future of 
Trials Combining Immunotherapy and Radiation Therapy. Int J Radiat Oncol 
Biol Phys. 2016;95:1254-1256. 
48. Karin M,Cao Y,Greten FR, Li ZW. NF-kappaB in cancer: from innocent 
bystander to major culprit. Nat Rev Cancer. 2002;2:301-310. 
49. Wang T,Zhang X, Li JJ. The role of NF-kappaB in the regulation of cell stress 
responses. Int Immunopharmacol. 2002;2:1509-1520. 
50. Aravindan S, Natarajan M, Ramraj SK, Pandian V, Khan FH, Herman TS, et al. 
Abscopal effect of low-LET gamma-radiation mediated through Rel protein 
signal transduction in a mouse model of nontargeted radiation response. 
Cancer Gene Ther. 2014;21:54-59. 
51. Broekgaarden M, Kos M, Jurg FA, van Beek AA, van Gulik TM, Heger M. 
Inhibition of NF-kappaB in Tumor Cells Exacerbates Immune Cell Activation 
Following Photodynamic Therapy. Int J Mol Sci. 2015;16:19960-19977. 
52. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key 
elements of proinflammatory signalling. Semin Immunol. 2000;12:85-98. 
53. Habraken Y, Piette J. NF-kappaB activation by double-strand breaks. Biochem 
Pharmacol. 2006;72:1132-1141. 
54. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. 
Sci STKE. 2006;2006:re13. 
55. Hsuan CF, Hsu HF, Tseng WK, Lee TL, Wei YF, Hsu KL, et al. Glossogyne 
tenuifolia Extract Inhibits TNF-alpha-Induced Expression of Adhesion 
Molecules in Human Umbilical Vein Endothelial Cells via Blocking the NF-kB 
Signaling Pathway. Molecules. 2015;20:16908-16923. 
56. Wahyudi S, Sargowo D. Green tea polyphenols inhibit oxidized LDL-induced 
NF-KB activation in human umbilical vein endothelial cells. Acta Med 
Indones. 2007;39:66-70. 
57. Guo G, Wang T, Gao Q, Tamae D, Wong P, Chen T, et al. Expression of ErbB2 
enhances radiation-induced NF-kappaB activation. Oncogene. 
2004;23:535-545. 
58. Cao N, Li S, Wang Z, Ahmed KM, Degnan ME, Fan M, et al. 
NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance. 
Radiat Res. 2009;171:9-21. 
59. Eckert F, Jelas I, Oehme M, Huber SM, Sonntag K, Welker C, et al. 
Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor 
control via abscopal effects in vivo. Oncoimmunology. 2017;6:e1323161. 
60. Sabatel H,Pirlot C,Piette J, Habraken Y. Importance of PIKKs in NF-kappaB 
activation by genotoxic stress. Biochem Pharmacol. 2011;82:1371-1383. 
61. Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res. 2011;21:71-85. 
 Theranostics 2019, Vol. 9, Issue 5 
 
 
http://www.thno.org 
1228 
62. Oeckinghaus A, Ghosh S. The NF-κB Family of Transcription Factors and Its 
Regulation. Cold Spring Harbor Perspectives in Biology. 2009;1:a000034. 
63. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. 
Oncogene. 2006;25:6680-6684. 
64. Huang TT,Wuerzberger-Davis SM,Wu ZH, Miyamoto S. Sequential 
modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates 
NF-kappaB activation by genotoxic stress. Cell. 2003;115:565-576. 
65. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB 
signaling. Cell Res. 2011;21:103-115. 
66. Simon PS, Bardhan K, Chen MR, Paschall AV, Lu C, Bollag RJ, et al. 
NF-kappaB functions as a molecular link between tumor cells and Th1/Tc1 T 
cells in the tumor microenvironment to exert radiation-mediated tumor 
suppression. Oncotarget. 2016;7:23395-23415. 
67. Jung M,Zhang Y,Lee S, Dritschilo A. Correction of radiation sensitivity in 
ataxia telangiectasia cells by a truncated I kappa B-alpha. Science. 
1995;268:1619-1621. 
68. Spiotto M,Fu YX, Weichselbaum RR. The intersection of radiotherapy and 
immunotherapy: mechanisms and clinical implications. Sci Immunol. 2016;1: 
69. Ouaaz F,Arron J,Zheng Y,Choi Y, Beg AA. Dendritic cell development and 
survival require distinct NF-kappaB subunits. Immunity. 2002;16:257-270. 
70. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. 
Consequences of cell death: exposure to necrotic tumor cells, but not primary 
tissue cells or apoptotic cells, induces the maturation of immunostimulatory 
dendritic cells. J Exp Med. 2000;191:423-434. 
71. Hou Y, Liang H, Rao E, Zheng W, Huang X, Deng L, et al. Non-canonical 
NF-kappaB Antagonizes STING Sensor-Mediated DNA Sensing in 
Radiotherapy. Immunity. 2018;49:490-503 e494. 
72. Ahmed MM, Hodge JW, Guha C, Bernhard EJ, Vikram B, Coleman CN. 
Harnessing the potential of radiation-induced immune modulation for cancer 
therapy. Cancer Immunol Res. 2013;1:280-284. 
73. Corso CD,Ali AN, Diaz R. Radiation-induced tumor neoantigens: imaging and 
therapeutic implications. Am J Cancer Res. 2011;1:390-412. 
74. Gallegos CE,Michelin S,Dubner D, Carosella ED. Immunomodulation of 
classical and non-classical HLA molecules by ionizing radiation. Cell 
Immunol. 2016;303:16-23. 
75. Smahel M. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated 
MHC Class I Expression. Int J Mol Sci. 2017;18: 
76. Perea F, Bernal M, Sanchez-Palencia A, Carretero J, Torres C, Bayarri C, et al. 
The absence of HLA class I expression in non-small cell lung cancer correlates 
with the tumor tissue structure and the pattern of T cell infiltration. Int J 
Cancer. 2017;140:888-899. 
77. Ugurel S, Uhlig D, Pfohler C, Tilgen W, Schadendorf D, Reinhold U. 
Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating 
monocytes from melanoma patients. Cancer Immunol Immunother. 
2004;53:551-559. 
78. Speiser P,Zeillinger R,Wiltschke C,Sedlak J, Chorvath B. IL-1 alpha induced, 
TNF alpha mediated HLA class II (DR) antigen up-regulation in a human 
ductal breast carcinoma cell line ZR-75-1. Neoplasma. 1993;40:137-140. 
79. Ibrahim EC, Aractingi S, Allory Y, Borrini F, Dupuy A, Duvillard P, et al. 
Analysis of HLA antigen expression in benign and malignant melanocytic 
lesions reveals that upregulation of HLA-G expression correlates with 
malignant transformation, high inflammatory infiltration and HLA-A1 
genotype. Int J Cancer. 2004;108:243-250. 
80. Michelin S,Gallegos CE,Dubner D,Favier B, Carosella ED. Ionizing radiation 
modulates the surface expression of human leukocyte antigen-G in a human 
melanoma cell line. Hum Immunol. 2009;70:1010-1015. 
81. Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, et al. Focal 
radiation therapy combined with 4-1BB activation and CTLA-4 blockade 
yields long-term survival and a protective antigen-specific memory response 
in a murine glioma model. PLoS One. 2014;9:e101764. 
82. Vanpouille-Box C,Pilones KA,Wennerberg E,Formenti SC, Demaria S. In situ 
vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. 
Vaccine. 2015;33:7415-7422. 
83. Vanpouille-Box C,Formenti SC, Demaria S. Toward Precision Radiotherapy 
for Use with Immune Checkpoint Blockers. Clin Cancer Res. 2018;24:259-265. 
84. Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, Garcia-Martinez E, 
Rudqvist NP, et al. Barriers to Radiation-Induced In Situ Tumor Vaccination. 
Front Immunol. 2017;8:229. 
85. Walker LS. Treg and CTLA-4: two intertwining pathways to immune 
tolerance. J Autoimmun. 2013;45:49-57. 
86. Wong HK, Wilson AJ, Gibson HM, Hafner MS, Hedgcock CJ, Berger CL, et al. 
Increased expression of CTLA-4 in malignant T-cells from patients with 
mycosis fungoides -- cutaneous T cell lymphoma. J Invest Dermatol. 
2006;126:212-219. 
87. Sansom DM. CD28, CTLA-4 and their ligands: who does what and to whom? 
Immunology. 2000;101:169-177. 
88. Bhattacharyya T,Purushothaman K,Puthiyottil SS,Bhattacharjee A, Muttah G. 
Immunological interactions in radiotherapy-opening a new window of 
opportunity. Ann Transl Med. 2016;4:51. 
89. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. 
CTLA-4 control over Foxp3+ regulatory T cell function. Science. 
2008;322:271-275. 
90. Shen Y,Hu GH,Kang HY,Tang XY, Hong SL. Allergen induced Treg response 
in the peripheral blood mononuclear cells (PBMCs) of patients with nasal 
polyposis. Asian Pac J Allergy Immunol. 2014;32:300-307. 
91. Nakanishi Y, Ikebuchi R, Chtanova T, Kusumoto Y, Okuyama H, Moriya T, et 
al. Regulatory T cells with superior immunosuppressive capacity emigrate 
from the inflamed colon to draining lymph nodes. Mucosal Immunol. 2017; 
92. Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, et al. Improved 
survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer 
patients. Sci Transl Med. 2014;6:238ra270. 
93. Topalian SL,Drake CG, Pardoll DM. Immune checkpoint blockade: a common 
denominator approach to cancer therapy. Cancer Cell. 2015;27:450-461. 
94. Muenst S,Soysal SD,Tzankov A, Hoeller S. The PD-1/PD-L1 pathway: 
biological background and clinical relevance of an emerging treatment target 
in immunotherapy. Expert Opin Ther Targets. 2015;19:201-211. 
95. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, 
White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor 
express high levels of PD-1 and are functionally impaired. Blood. 
2009;114:1537-1544. 
96. Tsai HF, Hsu PN. Cancer immunotherapy by targeting immune checkpoints: 
mechanism of T cell dysfunction in cancer immunity and new therapeutic 
targets. J Biomed Sci. 2017;24:35. 
97. Prima V,Kaliberova LN,Kaliberov S,Curiel DT, Kusmartsev S. 
COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in 
tumor-associated macrophages and myeloid-derived suppressor cells. Proc 
Natl Acad Sci U S A. 2017;114:1117-1122. 
98. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. 
Irradiation and anti-PD-L1 treatment synergistically promote antitumor 
immunity in mice. J Clin Invest. 2014;124:687-695. 
99. Hu ZI,Ho AY, McArthur HL. Combined Radiation Therapy and Immune 
Checkpoint Blockade Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 
2017;99:153-164. 
100. Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, et al. Radiation and 
PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother 
Oncol. 2017;124:98-103. 
101. Chao MP,Majeti R, Weissman IL. Programmed cell removal: a new obstacle in 
the road to developing cancer. Nat Rev Cancer. 2011;12:58-67. 
102. Brown E,Hooper L,Ho T, Gresham H. Integrin-associated protein: a 50-kD 
plasma membrane antigen physically and functionally associated with 
integrins. J Cell Biol. 1990;111:2785-2794. 
103. Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA. 
Integrin-associated protein is a receptor for the C-terminal domain of 
thrombospondin. J Biol Chem. 1996;271:21-24. 
104. Liu Y, Merlin D, Burst SL, Pochet M, Madara JL, Parkos CA. The role of CD47 
in neutrophil transmigration. Increased rate of migration correlates with 
increased cell surface expression of CD47. J Biol Chem. 2001;276:40156-40166. 
105. Lindberg FP, Bullard DC, Caver TE, Gresham HD, Beaudet AL, Brown EJ. 
Decreased resistance to bacterial infection and granulocyte defects in 
IAP-deficient mice. Science. 1996;274:795-798. 
106. Miyashita M, Ohnishi H, Okazawa H, Tomonaga H, Hayashi A, Fujimoto TT, 
et al. Promotion of neurite and filopodium formation by CD47: roles of 
integrins, Rac, and Cdc42. Mol Biol Cell. 2004;15:3950-3963. 
107. Reinhold MI,Lindberg FP,Kersh GJ,Allen PM, Brown EJ. Costimulation of T 
cell activation by integrin-associated protein (CD47) is an 
adhesion-dependent, CD28-independent signaling pathway. J Exp Med. 
1997;185:1-11. 
108. Maxhimer JB,Shih HB,Isenberg JS,Miller TW, Roberts DD. 
Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is 
tissue protective. Plast Reconstr Surg. 2009;124:1880-1889. 
109. Maxhimer JB, Soto-Pantoja DR, Ridnour LA, Shih HB, Degraff WG, Tsokos M, 
et al. Radioprotection in normal tissue and delayed tumor growth by blockade 
of CD47 signaling. Sci Transl Med. 2009;1:3ra7. 
110. McCracken MN,Cha AC, Weissman IL. Molecular Pathways: Activating T 
Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" 
Signals. Clin Cancer Res. 2015;21:3597-3601. 
111. van den Berg TK, van der Schoot CE. Innate immune 'self' recognition: a role 
for CD47-SIRPalpha interactions in hematopoietic stem cell transplantation. 
Trends Immunol. 2008;29:203-206. 
112. Barclay AN, Van den Berg TK. The interaction between signal regulatory 
protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic 
target. Annu Rev Immunol. 2014;32:25-50. 
113. Tsai RK, Discher DE. Inhibition of "self" engulfment through deactivation of 
myosin-II at the phagocytic synapse between human cells. J Cell Biol. 
2008;180:989-1003. 
114. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg 
FP. Role of CD47 as a marker of self on red blood cells. Science. 
2000;288:2051-2054. 
115. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is 
upregulated on circulating hematopoietic stem cells and leukemia cells to 
avoid phagocytosis. Cell. 2009;138:271-285. 
116. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, Jr., et al. 
CD47 is an adverse prognostic factor and therapeutic antibody target on 
human acute myeloid leukemia stem cells. Cell. 2009;138:286-299. 
117. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. 
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and 
eradicate non-Hodgkin lymphoma. Cell. 2010;142:699-713. 
118. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, et al. Identification, 
molecular characterization, clinical prognosis, and therapeutic targeting of 
 Theranostics 2019, Vol. 9, Issue 5 
 
 
http://www.thno.org 
1229 
human bladder tumor-initiating cells. Proc Natl Acad Sci U S A. 
2009;106:14016-14021. 
119. Manna PP, Frazier WA. CD47 mediates killing of breast tumor cells via 
Gi-dependent inhibition of protein kinase A. Cancer Res. 2004;64:1026-1036. 
120. Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B, 
et al. Cancer stem cells in basic science and in translational oncology: can we 
translate into clinical application? J Hematol Oncol. 2015;8:16. 
121. Fan D, Li Z, Zhang X, Yang Y, Yuan X, Yang M, et al. AntiCD3Fv fused to 
human interleukin-3 deletion variant redirected T cells against human acute 
myeloid leukemic stem cells. J Hematol Oncol. 2015;8:18. 
122. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. 
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic 
adhesion and actin-dependent, lysosome-mediated cell death in B-cell 
malignancies. Blood. 2011;117:4519-4529. 
123. Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 
antibodies promote phagocytosis and inhibit the growth of human myeloma 
cells. Leukemia. 2012;26:2538-2545. 
124. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. 
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic 
target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109:6662-6667. 
125. Schmid MC, Khan SQ, Kaneda MM, Pathria P, Shepard R, Louis TL, et al. 
Integrin CD11b activation drives anti-tumor innate immunity. Nat Commun. 
2018;9:5379. 
126. Soto-Pantoja DR, Terabe M, Ghosh A, Ridnour LA, DeGraff WG, Wink DA, et 
al. CD47 in the tumor microenvironment limits cooperation between 
antitumor T-cell immunity and radiotherapy. Cancer Res. 2014;74:6771-6783. 
127. Menaa C, Fan M, Lu HC, Alexandrou A, Juma S, Perks J, Li JJ. The dynamic 
change of CD47 expression promotes tumor burden, metastases and resistance 
of breast cancer cells to radiotherapy. Cancer Res. 2013; 73: AACR Poster: 4963. 
128. Soto-Pantoja DR, Miller TW, Pendrak ML, DeGraff WG, Sullivan C, Ridnour 
LA, et al. CD47 deficiency confers cell and tissue radioprotection by activation 
of autophagy. Autophagy. 2012;8:1628-1642. 
129. Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, et al. CD47 blockade triggers 
T cell-mediated destruction of immunogenic tumors. Nat Med. 
2015;21:1209-1215. 
130. Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, et al. Pre-Clinical 
Development of a Humanized Anti-CD47 Antibody with Anti-Cancer 
Therapeutic Potential. PLoS One. 2015;10:e0137345. 
131. Advani IF, Popplewell L, Forero-Torres A, Bartlett NL, Ghosh N, Kline JP, et 
al. Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 
with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: 
Initial phase 1b/2 results. In: Journal of Clinical Oncology. vol. 36; 2018. 
132. Liu X,Kwon H,Li Z, Fu YX. Is CD47 an innate immune checkpoint for tumor 
evasion? J Hematol Oncol. 2017;10:12. 
133. Miller TW, Soto-Pantoja DR, Schwartz AL, Sipes JM, DeGraff WG, Ridnour 
LA, et al. CD47 Receptor Globally Regulates Metabolic Pathways That Control 
Resistance to Ionizing Radiation. J Biol Chem. 2015;290:24858-24874. 
134. Betancur PA, Abraham BJ, Yiu YY, Willingham SB, Khameneh F, Zarnegar M, 
et al. A CD47-associated super-enhancer links pro-inflammatory signalling to 
CD47 upregulation in breast cancer. Nat Commun. 2017;8:14802. 
135. Duru N, Fan M, Candas D, Menaa C, Liu HC, Nantajit D, et al. 
HER2-associated radioresistance of breast cancer stem cells isolated from 
HER2-negative breast cancer cells. Clin Cancer Res. 2012;18:6634-6647. 
136. Cook KL, Soto-Pantoja DR. "UPRegulation" of CD47 by the endoplasmic 
reticulum stress pathway controls anti-tumor immune responses. Biomark 
Res. 2017;5:26. 
137. Cook KL, Soto-Pantoja DR, Clarke PA, Cruz MI, Zwart A, Warri A, et al. 
Endoplasmic Reticulum Stress Protein GRP78 Modulates Lipid Metabolism to 
Control Drug Sensitivity and Antitumor Immunity in Breast Cancer. Cancer 
Res. 2016;76:5657-5670. 
138. Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, et al. 
Immunogenic tumor cell death induced by chemoradiotherapy in patients 
with esophageal squamous cell carcinoma. Cancer Res. 2012;72:3967-3976. 
139. Onishi M, Okonogi N, Oike T, Yoshimoto Y, Sato H, Suzuki Y, et al. High 
linear energy transfer carbon-ion irradiation increases the release of the 
immune mediator high mobility group box 1 from human cancer cells. J Radiat 
Res. 2018;59:541-546. 
140. McFarland BC, Stewart J, Jr., Hamza A, Nordal R, Davidson DJ, Henkin J, et al. 
Plasminogen kringle 5 induces apoptosis of brain microvessel endothelial 
cells: sensitization by radiation and requirement for GRP78 and LRP1. Cancer 
Res. 2009;69:5537-5545. 
141. Klein B, Loven D, Lurie H, Rakowsky E, Nyska A, Levin I, et al. The effect of 
irradiation on expression of HLA class I antigens in human brain tumors in 
culture. J Neurosurg. 1994;80:1074-1077. 
142. Friedman EJ. Immune modulation by ionizing radiation and its implications 
for cancer immunotherapy. Curr Pharm Des. 2002;8:1765-1780. 
143. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al. 
Immune-mediated inhibition of metastases after treatment with local radiation 
and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 
2005;11:728-734. 
144. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti 
SC, et al. Fractionated but not single-dose radiotherapy induces an 
immune-mediated abscopal effect when combined with anti-CTLA-4 
antibody. Clin Cancer Res. 2009;15:5379-5388. 
145. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. 
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J 
Med. 2014;371:2189-2199. 
146. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 
blockade and stereotactic radiation produce long-term survival in mice with 
intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86:343-349. 
147. Ahmed KA, Stallworth DG, Kim Y, Johnstone PA, Harrison LB, Caudell JJ, et 
al. Clinical outcomes of melanoma brain metastases treated with stereotactic 
radiation and anti-PD-1 therapy. Ann Oncol. 2016;27:434-441. 
148. Soto-Pantoja DR,Isenberg JS, Roberts DD. Therapeutic Targeting of CD47 to 
Modulate Tissue Responses to Ischemia and Radiation. J Genet Syndr Gene 
Ther. 2011;2: 
149. So T,Lee SW, Croft M. Immune regulation and control of regulatory T cells by 
OX40 and 4-1BB. Cytokine Growth Factor Rev. 2008;19:253-262. 
150. Baumann R, Yousefi S, Simon D, Russmann S, Mueller C, Simon HU. 
Functional expression of CD134 by neutrophils. Eur J Immunol. 
2004;34:2268-2275. 
151. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk 
between activated human NK cells and CD4+ T cells via OX40-OX40 ligand 
interactions. J Immunol. 2004;173:3716-3724. 
152. Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich B, et al. Plasmacytoid 
dendritic cells induce NK cell-dependent, tumor antigen-specific T cell 
cross-priming and tumor regression in mice. J Clin Invest. 2008;118:1165-1175. 
153. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear 
weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331-342. 
154. Zhu J, Luo J, Li Y, Jia M, Wang Y, Huang Y, et al. HMGB1 induces human 
non-small cell lung cancer cell motility by activating integrin 
alphavbeta3/FAK through TLR4/NF-kappaB signaling pathway. Biochem 
Biophys Res Commun. 2016;480:522-527. 
155. Yue Y, Zhou T, Gao Y, Zhang Z, Li L, Liu L, et al. High mobility group box 
1/toll-like receptor 4/myeloid differentiation factor 88 signaling promotes 
progression of gastric cancer. Tumour Biol. 2017;39:1010428317694312. 
156. Li Z, Block MS, Vierkant RA, Fogarty ZC, Winham SJ, Visscher DW, et al. The 
inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 
and MyD88 and related proteins. Tumour Biol. 2016;37:13279-13286. 
157. He S, Cheng J, Sun L, Wang Y, Wang C, Liu X, et al. HMGB1 released by 
irradiated tumor cells promotes living tumor cell proliferation via paracrine 
effect. Cell Death Dis. 2018;9:648. 
158. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. 
Cancer Res. 2007;67:3496-3499. 
159. Gifford JB, Hill R. GRP78 Influences Chemoresistance and Prognosis in 
Cancer. Curr Drug Targets. 2018;19:701-708. 
160. Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, et al. 
Glucose-regulated protein GRP78 is up-regulated in prostate cancer and 
correlates with recurrence and survival. Hum Pathol. 2007;38:1547-1552. 
161. Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol 
Med. 2006;6:45-54. 
162. Zhai L, Kita K, Wano C, Wu Y, Sugaya S, Suzuki N. Decreased cell survival 
and DNA repair capacity after UVC irradiation in association with 
down-regulation of GRP78/BiP in human RSa cells. Exp Cell Res. 
2005;305:244-252. 
163. Misra UK,Gonzalez-Gronow M,Gawdi G, Pizzo SV. The role of MTJ-1 in cell 
surface translocation of GRP78, a receptor for alpha 
2-macroglobulin-dependent signaling. J Immunol. 2005;174:2092-2097. 
164. Choi HJ, Choi WS, Park JY, Prabagar MG, Kang KH, Jeon SJ, et al. SIGN-R1, a 
C-type lectin, binds to Bip/GRP78 and this interaction mediates the 
regurgitation of T-cell-independent type 2 antigen dextran through the 
endoplasmic reticulum. Immunobiology. 2011;216:437-446. 
165. Wei D, Li NL, Zeng Y, Liu B, Kumthip K, Wang TT, et al. The Molecular 
Chaperone GRP78 Contributes to Toll-like Receptor 3-mediated Innate 
Immune Response to Hepatitis C Virus in Hepatocytes. J Biol Chem. 
2016;291:12294-12309. 
166. Rasche L, Duell J, Castro IC, Dubljevic V, Chatterjee M, Knop S, et al. 
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - 
results from a phase 1 trial with the monoclonal immunoglobulin M antibody 
PAT-SM6. Haematologica. 2015;100:377-384. 
167. Li B,Cheng XL,Yang YP, Li ZQ. GRP78 mediates radiation resistance of a stem 
cell-like subpopulation within the MCF-7 breast cancer cell line. Oncol Rep. 
2013;30:2119-2126. 
168. Dadey DYA, Kapoor V, Hoye K, Khudanyan A, Collins A, Thotala D, et al. 
Antibody Targeting GRP78 Enhances the Efficacy of Radiation Therapy in 
Human Glioblastoma and Non-Small Cell Lung Cancer Cell Lines and Tumor 
Models. Clin Cancer Res. 2017;23:2556-2564. 
169. Croft M,So T,Duan W, Soroosh P. The significance of OX40 and OX40L to 
T-cell biology and immune disease. Immunol Rev. 2009;229:173-191. 
170. Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, et al. OX40 
costimulation turns off Foxp3+ Tregs. Blood. 2007;110:2501-2510. 
171. Moran AE,Polesso F, Weinberg AD. Immunotherapy Expands and Maintains 
the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ. J 
Immunol. 2016;197:2509-2521. 
172. Yokouchi H, Yamazaki K, Chamoto K, Kikuchi E, Shinagawa N, Oizumi S, et 
al. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy 
results in therapeutic antitumor immunity to murine lung cancer. Cancer Sci. 
2008;99:361-367. 
 Theranostics 2019, Vol. 9, Issue 5 
 
 
http://www.thno.org 
1230 
173. Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, et al. 
Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local 
control after surgical or radiation therapy of cancer in mice. J Immunother. 
2010;33:798-809. 
174. Mikulandra M,Pavelic J, Glavan TM. Recent findings on the application of 
Toll-like receptors agonists in cancer therapy. Curr Med Chem. 2017; 
175. Cho JH, Lee HJ, Ko HJ, Yoon BI, Choe J, Kim KC, et al. The TLR7 agonist 
imiquimod induces anti-cancer effects via autophagic cell death and enhances 
anti-tumoral and systemic immunity during radiotherapy for melanoma. 
Oncotarget. 2017;8:24932-24948. 
176. Scholch S,Rauber C,Weitz J,Koch M, Huber PE. TLR activation and ionizing 
radiation induce strong immune responses against multiple tumor entities. 
Oncoimmunology. 2015;4:e1042201. 
177. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. 
Toll-like receptor 4-dependent contribution of the immune system to 
anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050-1059. 
178. Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, 
et al. Systemic delivery of a TLR7 agonist in combination with radiation 
primes durable antitumor immune responses in mouse models of lymphoma. 
Blood. 2013;121:251-259. 
179. Malamas AS,Gameiro SR,Knudson KM, Hodge JW. Sublethal exposure to 
alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to 
lysis by antigen-specific cytotoxic T lymphocytes through 
calreticulin-mediated immunogenic modulation. Oncotarget. 
2016;7:86937-86947. 
180. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. 
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat 
Med. 2007;13:54-61. 
181. Nabet BY, Qiu Y, Shabason JE, Wu TJ, Yoon T, Kim BC, et al. Exosome RNA 
Unshielding Couples Stromal Activation to Pattern Recognition Receptor 
Signaling in Cancer. Cell. 2017;170:352-366 e313. 
182. Kim SH,Turnbull J, Guimond S. Extracellular matrix and cell signalling: the 
dynamic cooperation of integrin, proteoglycan and growth factor receptor. J 
Endocrinol. 2011;209:139-151. 
183. Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in 
cancer. Trends Cell Biol. 2015;25:198-213. 
184. Kauppila S,Stenback F,Risteli J,Jukkola A, Risteli L. Aberrant type I and type 
III collagen gene expression in human breast cancer in vivo. J Pathol. 
1998;186:262-268. 
185. Kumar S,Kapoor A,Desai S,Inamdar MM, Sen S. Proteolytic and 
non-proteolytic regulation of collective cell invasion: tuning by ECM density 
and organization. Sci Rep. 2016;6:19905. 
186. Su C, Zhang B, Liu W, Zheng H, Sun L, Tong J, et al. High extracellular 
pressure promotes gastric cancer cell adhesion, invasion, migration and 
suppresses gastric cancer cell differentiation. Oncol Rep. 2016;36:1048-1054. 
187. Jerrell RJ, Parekh A. Matrix rigidity differentially regulates invadopodia 
activity through ROCK1 and ROCK2. Biomaterials. 2016;84:119-129. 
188. Moeller BJ,Cao Y,Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate 
vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and 
stress granules. Cancer Cell. 2004;5:429-441. 
189. Schito L, Semenza GL. Hypoxia-Inducible Factors: Master Regulators of 
Cancer Progression. Trends Cancer. 2016;2:758-770. 
190. Semenza GL. The hypoxic tumor microenvironment: A driving force for breast 
cancer progression. Biochim Biophys Acta. 2016;1863:382-391. 
191. Koltai T. Cancer: fundamentals behind pH targeting and the double-edged 
approach. Onco Targets Ther. 2016;9:6343-6360. 
192. Brat DJ,Kaur B, Van Meir EG. Genetic modulation of hypoxia induced gene 
expression and angiogenesis: relevance to brain tumors. Front Biosci. 
2003;8:d100-116. 
193. Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, et al. Lipocalin 2 
is essential for chronic kidney disease progression in mice and humans. J Clin 
Invest. 2010;120:4065-4076. 
194. Abramsson A,Lindblom P, Betsholtz C. Endothelial and nonendothelial 
sources of PDGF-B regulate pericyte recruitment and influence vascular 
pattern formation in tumors. J Clin Invest. 2003;112:1142-1151. 
195. Alexander S, Friedl P. Cancer invasion and resistance: interconnected 
processes of disease progression and therapy failure. Trends Mol Med. 
2012;18:13-26. 
196. Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, et al. 
beta4 integrin-dependent formation of polarized three-dimensional 
architecture confers resistance to apoptosis in normal and malignant 
mammary epithelium. Cancer Cell. 2002;2:205-216. 
197. Vehlow A,Storch K,Matzke D, Cordes N. Molecular Targeting of Integrins and 
Integrin-Associated Signaling Networks in Radiation Oncology. Recent 
Results Cancer Res. 2016;198:89-106. 
198. Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, et al. 
Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma 
modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A. 
2011;108:15336-15341. 
199. Perrino FW,Miller H, Ealey KA. Identification of a 3'-->5'-exonuclease that 
removes cytosine arabinoside monophosphate from 3' termini of DNA. J Biol 
Chem. 1994;269:16357-16363. 
200. Hoss M, Robins P, Naven TJ, Pappin DJ, Sgouros J, Lindahl T. A human DNA 
editing enzyme homologous to the Escherichia coli DnaQ/MutD protein. 
EMBO J. 1999;18:3868-3875. 
201. Namjou B, Kothari PH, Kelly JA, Glenn SB, Ojwang JO, Adler A, et al. 
Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes 
Immun. 2011;12:270-279. 
202. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, 
Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced 
tumour immunogenicity. Nat Commun. 2017;8:15618. 
203. Vanpouille-Box C,Formenti SC, Demaria S. TREX1 dictates the immune fate of 
irradiated cancer cells. Oncoimmunology. 2017;6:e1339857. 
204. Malecka A, Wang Q, Shah S, Sutavani RV, Spendlove I, Ramage JM, et al. 
Stromal fibroblasts support dendritic cells to maintain IL-23/Th17 responses 
after exposure to ionizing radiation. J Leukoc Biol. 2016;100:381-389. 
205. Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H. 
Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor 
Growth. Cancers (Basel). 2015;7:2443-2458. 
206. Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor 
signaling and extracellular matrix remodeling to regulate tumor metastasis. 
Biochem Soc Trans. 2017;45:229-236. 
207. Erez N,Glanz S,Raz Y,Avivi C, Barshack I. Cancer associated fibroblasts 
express pro-inflammatory factors in human breast and ovarian tumors. 
Biochem Biophys Res Commun. 2013;437:397-402. 
208. Nam JS, Suchar AM, Kang MJ, Stuelten CH, Tang B, Michalowska AM, et al. 
Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of 
transforming growth factor beta in a mouse model of breast cancer. Cancer 
Res. 2006;66:6327-6335. 
209. Kramer N, Schmollerl J, Unger C, Nivarthi H, Rudisch A, Unterleuthner D, et 
al. Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer 
progression. Oncogene. 2017;36:5460-5472. 
210. Verbovsek U,Van Noorden CJ, Lah TT. Complexity of cancer protease biology: 
Cathepsin K expression and function in cancer progression. Semin Cancer 
Biol. 2015;35:71-84. 
211. Silva AM, Almeida MI, Teixeira JH, Maia AF, Calin GA, Barbosa MA, et al. 
Dendritic Cell-derived Extracellular Vesicles mediate Mesenchymal 
Stem/Stromal Cell recruitment. Sci Rep. 2017;7:1667. 
212. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, 
et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces 
immunosuppression and accelerates pancreas cancer with reduced survival. 
Cancer Cell. 2014;25:719-734. 
213. Lehmann B, Biburger M, Bruckner C, Ipsen-Escobedo A, Gordan S, Lehmann 
C, et al. Tumor location determines tissue-specific recruitment of 
tumor-associated macrophages and antibody-dependent immunotherapy 
response. Sci Immunol. 2017;2: 
214. Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, et al. 
Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic 
Ductal Adenocarcinoma. Clin Cancer Res. 2017;23:137-148. 
215. Graves DT,Jiang YL,Williamson MJ, Valente AJ. Identification of monocyte 
chemotactic activity produced by malignant cells. Science. 1989;245:1490-1493. 
216. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits 
inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 
2011;475:222-225. 
217. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. 
IRF5 promotes inflammatory macrophage polarization and TH1-TH17 
responses. Nat Immunol. 2011;12:231-238. 
218. Mantovani A, Allavena P. The interaction of anticancer therapies with 
tumor-associated macrophages. J Exp Med. 2015;212:435-445. 
219. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J 
Clin Invest. 2012;122:787-795. 
220. Gupta DK,Singh N, Sahu DK. TGF-beta Mediated Crosstalk Between 
Malignant Hepatocyte and Tumor Microenvironment in Hepatocellular 
Carcinoma. Cancer Growth Metastasis. 2014;7:1-8. 
221. Loinard C,Vilar J,Milliat F,Levy B, Benderitter M. Monocytes/Macrophages 
Mobilization Orchestrate Neovascularization after Localized Colorectal 
Irradiation. Radiat Res. 2017;187:549-561. 
222. Jiang S, Yang Y, Fang M, Li X, Yuan X, Yuan J. Co-evolution of 
tumor-associated macrophages and tumor neo-vessels during cervical cancer 
invasion. Oncol Lett. 2016;12:2625-2631. 
223. Kim CJ, Tambe Y, Mukaisho KI, Sugihara H, Kageyama S, Kawauchi A, et al. 
Periostin suppresses in vivo invasiveness via PDK1/Akt/mTOR signaling 
pathway in a mouse orthotopic model of bladder cancer. Oncol Lett. 
2017;13:4276-4284. 
224. Jang SY, Park SY, Lee HW, Choi YK, Park KG, Yoon GS, et al. The 
Combination of Periostin Overexpression and Microvascular Invasion Is 
Related to a Poor Prognosis for Hepatocellular Carcinoma. Gut Liver. 
2016;10:948-954. 
225. Li Z, Zhang X, Yang Y, Yang S, Dong Z, Du L, et al. Periostin expression and 
its prognostic value for colorectal cancer. Int J Mol Sci. 2015;16:12108-12118. 
226. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages 
regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 
2006;66:11238-11246. 
227. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. 
Arginase I production in the tumor microenvironment by mature myeloid 
cells inhibits T-cell receptor expression and antigen-specific T-cell responses. 
Cancer Res. 2004;64:5839-5849. 
228. Guo Q, Jin Z, Yuan Y, Liu R, Xu T, Wei H, et al. New Mechanisms of 
Tumor-Associated Macrophages on Promoting Tumor Progression: Recent 
 Theranostics 2019, Vol. 9, Issue 5 
 
 
http://www.thno.org 
1231 
Research Advances and Potential Targets for Tumor Immunotherapy. J 
Immunol Res. 2016;2016:9720912. 
229. Zhao X, Qu J, Sun Y, Wang J, Liu X, Wang F, et al. Prognostic significance of 
tumor-associated macrophages in breast cancer: a meta-analysis of the 
literature. Oncotarget. 2017;8:30576-30586. 
230. Pinto AT, Pinto ML, Velho S, Pinto MT, Cardoso AP, Figueira R, et al. Intricate 
Macrophage-Colorectal Cancer Cell Communication in Response to Radiation. 
PLoS One. 2016;11:e0160891. 
231. Prakash H, Klug F, Nadella V, Mazumdar V, Schmitz-Winnenthal H, 
Umansky L. Low doses of gamma irradiation potentially modifies 
immunosuppressive tumor microenvironment by retuning tumor-associated 
macrophages: lesson from insulinoma. Carcinogenesis. 2016;37:301-313. 
232. Kung WH, Yu CF, Lee AC, Yang CD, Liu YC, Chen FH, et al. Gene expression 
profiling of tumor-associated macrophages after exposure to single-dose 
irradiation. Comput Biol Chem. 2017;69:138-146. 
233. Allaoui R, Bergenfelz C, Mohlin S, Hagerling C, Salari K, Werb Z, et al. 
Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote 
stroma activation in triple-negative breast cancers. Nat Commun. 
2016;7:13050. 
234. Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, et al. 
Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by 
Both Resident and Infiltrating Polyclonal T-cell Populations when Combined 
with PD-1 Blockade. Clin Cancer Res. 2017;23:5514-5526. 
235. Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, et al. 
Concurrent radiotherapy and ipilimumab immunotherapy for patients with 
melanoma. Cancer Immunol Res. 2013;1:92-98. 
236. Kapoor V, Dadey DY, Nguyen K, Wildman SA, Hoye K, Khudanyan A, et al. 
Tumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel 
Agent for Targeting Cancers. J Nucl Med. 2016;57:1991-1997. 
237. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et 
al. Acquired resistance to fractionated radiotherapy can be overcome by 
concurrent PD-L1 blockade. Cancer Res. 2014;74:5458-5468. 
238. Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian 
M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating 
factor to generate abscopal responses in patients with metastatic solid 
tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795-803. 
239. Kordbacheh T,Honeychurch J,Blackhall F,Faivre-Finn C, Illidge T. 
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building 
better translational research platforms. Ann Oncol. 2018;29:301-310. 
240. Walshaw RC,Honeychurch J,Illidge TM, Choudhury A. The anti-PD-1 era - an 
opportunity to enhance radiotherapy for patients with bladder cancer. Nat 
Rev Urol. 2018;15:251-259. 
241. Herter-Sprie GS, Koyama S, Korideck H, Hai J, Deng J, Li YY, et al. Synergy of 
radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 
2016;1:e87415. 
242. Martinov T, Fife BT. Fractionated radiotherapy combined with PD-1 pathway 
blockade promotes CD8 T cell-mediated tumor clearance for the treatment of 
advanced malignancies. Ann Transl Med. 2016;4:82. 
243. Roger A, Finet A, Boru B, Beauchet A, Mazeron JJ, Otzmeguine Y, et al. 
Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 
monotherapy in difficult-to-treat advanced melanoma patients. 
Oncoimmunology. 2018;7:e1442166. 
244. Reynders K, De Ruysscher D. Radiotherapy and Immunotherapy: Improving 
Cancer Treatment through Synergy. Prog Tumor Res. 2015;42:67-78. 
245. Tazi K,Hathaway A,Chiuzan C, Shirai K. Survival of melanoma patients with 
brain metastases treated with ipilimumab and stereotactic radiosurgery. 
Cancer Med. 2015;4:1-6. 
246. Aboudaram A, Modesto A, Chaltiel L, Gomez-Roca C, Boulinguez S, Sibaud 
V, et al. Concurrent radiotherapy for patients with metastatic melanoma and 
receiving anti-programmed-death 1 therapy: a safe and effective combination. 
Melanoma Res. 2017;27:485-491. 
247. Koller KM, Mackley HB, Liu J, Wagner H, Talamo G, Schell TD, et al. 
Improved survival and complete response rates in patients with advanced 
melanoma treated with concurrent ipilimumab and radiotherapy versus 
ipilimumab alone. Cancer Biol Ther. 2017;18:36-42. 
248. Frydenlund N, Mahalingam M. PD-L1 and immune escape: insights from 
melanoma and other lineage-unrelated malignancies. Hum Pathol. 
2017;66:13-33. 
 
